WO1999050255A2 - Disubstituted pyrazolines and triazolines as factor xa inhibitors - Google Patents

Disubstituted pyrazolines and triazolines as factor xa inhibitors Download PDF

Info

Publication number
WO1999050255A2
WO1999050255A2 PCT/US1999/006310 US9906310W WO9950255A2 WO 1999050255 A2 WO1999050255 A2 WO 1999050255A2 US 9906310 W US9906310 W US 9906310W WO 9950255 A2 WO9950255 A2 WO 9950255A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
occurrence
imidazolyl
pyridyl
substituted
Prior art date
Application number
PCT/US1999/006310
Other languages
French (fr)
Other versions
WO1999050255A3 (en
Inventor
Donald J. P. Pinto
Original Assignee
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharmaceuticals Company filed Critical Du Pont Pharmaceuticals Company
Priority to AU31109/99A priority Critical patent/AU3110999A/en
Priority to EP99912828A priority patent/EP1064270B1/en
Priority to AT99912828T priority patent/ATE278673T1/en
Priority to CA002321538A priority patent/CA2321538A1/en
Priority to JP2000541159A priority patent/JP2002509924A/en
Priority to DE69920888T priority patent/DE69920888T2/en
Publication of WO1999050255A2 publication Critical patent/WO1999050255A2/en
Publication of WO1999050255A3 publication Critical patent/WO1999050255A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

The present application describes disubstituted pyrazolines and triazolines of formulae (I) and (II), or pharmaceutically acceptable salt forms thereof, wherein one of M?1 and M2¿ may be N and D may be a variety of N-containing groups, which are useful as inhibitors of factor Xa.

Description

TITLE DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA
INHIBITORS
FIELD OF THE INVENTION
This invention relates generally to disubstituted pyrazolines and triazolines which are inhibitors of trypsin- like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
BACKGROUND OF THE INVENTION WO 95/18111 addresses fibrinogen receptor antagonists, containing basic and acidic termini, of the formula:
Figure imgf000003_0001
wherein R1 represents the basic termini, U is an alkylene or heteroatom linker, V may be a heterocycle, and the right hand portion of the molecule represents the acidic termini. The presently claimed compounds do not contain the acidic termini of WO 95/18111. In U.S. Patent No. 5,463,071, Himmelsbach et al depict cell aggregation inhibitors which are 5-membered heterocycles of the formula :
Figure imgf000003_0002
wherein the heterocycle may be aromatic and groups A-B-C- and F-E-D- are attached to the ring system. A-B-C- can be a wide variety of substituents including a basic group attached to an aromatic ring. The F-E-D- group, however, would appear to be an acidic functionality which differs from the present invention. Furthermore, use of these compounds as inhibitors of factor Xa is not discussed.
WO 97/47299 describes amidino and guanidino heterocyclic protease inhibitors of the formula: Ri-Z-X-Y-W wherein W contains an amidino, guanidino, or imino group attached to a variety of moieties including phenyl and piperidinyl, Y is a 0, N, S, or C linker or is absent, X is a heterocycle, Z is a two atom linker containing at least one heteroatom, and R1 is a variety of groups including cycloalkyl, aryl, heteroaryl, and araalkyl all of which are optionally substituted. A variety of proteases are described as possible targets for these compounds including Factor Xa. The presently claimed compounds differ in that they do not contain the combination R1-Z or Y-W.
WO 97/23212 describes isoxazolines , isothiazolines, and pyrazolines of the formula:
Figure imgf000004_0001
wherein X is O, S or NR15. Though the pyrazolines of WO 97/23212 are indicated to be factor Xa inhibitors, they are not considered part of the present invention.
Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V, Ca2+ and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimization of conditions for the catalytic effect of the factor IXa-factor VIII Complex: Probable role of the complex in the amplification of blood coagulation . Thromb. Res . 1979, 15, 617-629), inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system.
Therefore, efficacious and specific inhibitors of factor Xa are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders . It is thus desirable to discover new factor Xa inhibitors.
SUMMARY OF THE INVENTION Accordingly, one object of the present invention is to provide novel disubstituted pyrazolines and triazolines which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof .
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof .
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors' discovery that compounds of formulae I and II:
Figure imgf000006_0001
I II or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, D, E, G, M, Z, Rl , Rlb, and s are defined below, are effective factor Xa inhibitors.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [1] Thus, in a first embodiment, the present invention provides novel compounds of formulae I or II:
Figure imgf000006_0002
I II
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
M1 is N or CRlc;
M2 is NRla or CRlaRla, provided that only one of M1 and M2 is a N atom;
D is selected from C (=NR8) NR7R9 , NHC (=NR8)NR7R9 , NR8CH(=NR7), C(0)NR7R8, and CR8R9NR7R8;
E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1 R;
alternatively, D-E-G together represent pyridyl substituted with 1 R; R is selected from H, Cl, F, Br, I, (CH )t0R3, C1-4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9 ) tNR7R8 ;
G is selected from NHCH , OCH , and SCH2, provided that when s is 0, then G is absent;
Z is selected from a C1-4 alkylene, (CH2) rO (CH ) r,
(CH2)rNR3(CH2)r, (CH2)rC(0) (CH2)r, (CH2 ) rC (0) O (CH2) r, (CH2)r0C(0) (CH2)r, (CH2)rC(0)NR3(CH2)r, (CH2)rNR3C(0) (CH2)r, (CH2) rOC (0) O (CH2 ) r, (CH2)rOC(0)NR3(CH2)r, (CH2)rNR3C(0)0(CH2)r, (CH2)rNRC(0)NR3 (CH2)r, (CH2 ) rS (0) p (CH2) r, (CH2)rS02NR3(CH2)r, (CH2)rNR3S02(CH2)r, and (CH2)rNR3S02NR3 (CH )r, provided that Z does not form a N- N, N-0, N-S, NCH2N, NCH20, or NCH2S bond with group A;
Rl and Rlb are, at each occurrence, independently selected from H, -(CH2)r-R1'/ NCH2R1", OCH2R1", SCH2R1", N(CH2)2(CH2)tR1', 0(CH2)2(CH2)tR1', and S (CH2) 2 (CH2) R1' ;
RIC is selected from H, -(CH2)q-R1', Cι_3 alkyl, C(0)R2c, (CF2)rCθ2R2c, C(0)NR2R2a, C3-.6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
R1' is selected from H, C1-.3 alkyl, halo, (CF )rCF3, OR2, NR2R2a, C(0)R2c, OC(0)R2, (CF2) rC02R2c, S(0)pR2b, NR2(CH2)rOR2, NR2C(0)R2b, NR2C (0)NHR2b, NR2C(0)2R2a, OC(0)NR2b, C(0)NR2R2a, S02NR2R2a, NR2S02R2b, C3-6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
R1" is selected from H, C(0)R2b, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a; R2, at each occurrence, is selected from H, CF3, Cχ-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
Ra, at each occurrence, is selected from H, CF3 , Cχ_6 alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
R2b, at each occurrence, is selected from CF3 , C1-4 alkoxy, C1-6 alkyl, benzyl, C3-.6 carbocyclic residue substituted with 0-2 Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 Rb;
R2c, at each occurrence, is selected from CF3, OH, Cι_4 alkoxy, C1-6 alkyl, benzyl, C3-.6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 Rb;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3 , at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
R3a, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
A is selected from: C3-10 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
B is selected from:
X-Y, NR2R2a, C(=NR2)NR2R2a, NR2C (=NR2 )NR2R2a, C3-10 carbocyclic residue substituted with 0-2 R a, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
X is selected from C1-4 alkylene, -CR2 (CR2R2b) (CH2) t-, -C(O)-, -C(=NR)-, -CR2(NR1"R2)-, -CR2(OR2)-, -CR2(SR2)-, -C(0)CR2R2a-, -CR2R2 C(0), -S(0)p-, -S (O) pCR2R2a- ,
-CR2R2aS(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (0) 2CR2R2 -, -CR2R2aS(0)2NR2-, -NR2S(0) NR2-, -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C(0)CR2R2a-, -CR2R2aC (O)NR2-, -CR2R2 NR2C(0)-, -NR2C(0)0-, -0C(0)NR2-, -NR2C (O)NR2-, -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO- , and -OCR2R2a- ;
Y is selected from:
(CH2)rNR2R2a, provided that X-Y do not form a N-N, O-N, or S-N bond,
C3_ιo carbocyclic residue substituted with 0-2 R4 , and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from =0, (CH2)rOR2, halo, C1-4 alkyl, -CN, N02, (CH2) rNR2R2a, (CH2) rC (0)R2b, NR2C(0)R2b, C(0)NR2R2a, NR2C (0)NR2R2a, CH (=NR2)NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S0NR2R2a, NR2S02-Cι_ alkyl, NR2S0 R5, S(0)pR5, (CF2)rCF3, NCH2R1", OCH2R1", SCH2R1", N(CH2)2(CH2)tRl', 0 (CH2) 2 (CH2) tR1 ' , and S(CH2)2(CH2)tR1', alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S;
R4a, at each occurrence, is selected from =0, (CH )rOR2, halo, Cι-4 alkyl, -CN, N02, (CH2) rNRR2a, (CH ) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, NR2C (0)NR2R2a, CH (=NR2 ) NR2R2 , NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-C1_4 alkyl, NR2S02R5, S(0)PR5, and (CF2)rCF3;
alternatively, one R4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R5;
Rb, at each occurrence, is selected from =0, (CH )rOR3, halo, Ci-4 alkyl, -CN, N02, (CH2 ) rNR3R3a, (CH2) rC (0) R3 , NR3C(0)R3a, C(0)NR3R3a, NR3C (0)NR3R3a, CH(=NR3 )NR3R3a, NH3C(=NR3)NR3R3a, S02NR3R3a, NR3S02NR3R3a, NR3S02-Ci- alkyl, NR3S0CF3, NR3S02-phenyl , S(0)pCF3/ S(0)p-Cι_4 alkyl, S (0)p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF3 , C -β alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6 , at each occurrence, is selected from H, OH, (CH )r0R2, halo, C1-4 alkyl, CN, N02 , (CH2) rNR R2a, (CH2) rC (0)R2b, NR2C(0)R2b, NR2C(0)NR R2a, CH(=NH)NH2, NHC(=NH)NH2, S0 NR2R a, NR2S02NR2R2a, and NR2S02Cι_4 alkyl;
R7, at each occurrence, is selected from H, OH, C1-6 alkyl, Cι_6 alkylcarbonyl , C1-6 alkoxy, Cχ_4 alkoxycarbonyl , (CH2)n-phenyl, C6-10 aryloxy, Cβ-io aryloxycarbonyl , Cβ-io arylmethylcarbonyl , Cι_4 alkylcarbonyloxy C1-4 alkoxycarbonyl, C6_ιo arylcarbonyloxy C1-4 alkoxycarbonyl, C1-6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl C1-4 alkoxycarbonyl; R8, at each occurrence, is selected from H, Cι_6 alkyl and (CH2)n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R9, at each occurrence, is selected from H, C__6 alkyl and (CH2)n-phenyl;
n, at each occurrence, is selected from 0, 1, 2, and 3 ;
m, at each occurrence, is selected from 0, 1, and 2;
p, at each occurrence, is selected from 0, 1, and 2 ;
q, at each occurrence is selected from 1 and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0 and 1.
[2 ] In a preferred embodiment , the present invention provides novel compounds of formulae la-lb :
Figure imgf000011_0001
wherein; Z is selected from a CH20, OCH2, CH2NH, NHCH2, C(O), CHC(0), C(0)CH2, NHC(O), C(0)NH, CH2S(0)2, S(0)2(CH2), S02NH, and NHS0 , provided that Z does not form a N-N, N-O, NCH2N, or NCH20 bond with group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl , piperidinyl , piperazinyl , pyridyl , pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl , triazolyl, 1, 2, 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1, 2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1, 2, 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4- riazolyl, benzofuranyl , benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2 , and NR2C(=NR2)NR2R2a;
X is selected from C1-.4 alkylene, -C(O)-, -C(=NR)-, -CR2(NR2R2a)-, -C(0)CR2R2a-, -CR2R2aC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (0) CR2R2a-, -CR2R2aC(0)NR2-, -CR2R2aNR2C(0)-, -NR2C (0) NR2- , -NR2-, -NR2CR2R2 -, -CR2R2aNR2-, O, -CR2R2a0-, and -0CR2R2a-;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 Ra; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl,
1, 2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl,
1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl,
1,2,4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl , benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems:
Figure imgf000013_0001
K is selected from O, S, NH, and N.
[3] In a more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
Z is selected from a C(O), CH2C(0), C(0)CH2, NHC(O), C(0)NH, C(0)N(CH3), CH2S(0)2, S(0)2(CH2), S02NH, and NHS02 , provided that Z does not form a N-N or NCH2N bond with group A.
[4] In an even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R; D is selected from C(0)NH2, C(=NH)NH2, CH2NH2, CH2NHCH3, CH(CH3)NH2, and C(CH3)2NH2; and,
R is selected from H, OCH3, Cl, and F.
[5] In a further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3 - (methylaminomethyl) phenyl, 3- ( 1- aminoethyl) phenyl , 3- (2-amino-2-propyl) phenyl, 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl)phenyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, and 6- (2-amino-2-propyl)pyrid-2-yl.
[6] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2 , 3-triazolyl, and imidazolyl, and is substituted with 0-1 Ra;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo, Cι_4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3; R 4a is selected from Cι_4 alkyl, CF3 , S(0)pR5, S0NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cι_6 alkyl, phenyl, and benzyl ;
X is CH2 or C(O); and,
Y is selected from pyrrolidino and morpholino.
[7] In another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl; and,
B is selected from the group: 2-CF3-phenyl , 2-
(aminosulfonyl)phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3-tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3-triazolyl .
[8] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from C(0)NH2, C(=NH)NH2, CH2NH2, CH2NHCH3 , CH(CH3)NH2, and C(CH3)2NH2; and,
R is selected from H, OCH3, Cl, and F; Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 Ra;
R4, at each occurrence, is selected from OH, (CH )rOR2, halo, Cι-4 alkyl, (CH2) rNRR2a, and (CF2)rCF3;
Ra is selected from Cι_ alkyl, CF3, S(0)pR5, S0NR2R2 , and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, Cι-β alkyl, phenyl , and benzyl,-
X is CH or C(O); and,
Y is selected from pyrrolidino and morpholino ,
[9] In another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3 - (methylaminomethyl) phenyl, 3- ( 1- aminoethyl)phenyl, 3- (2-amino-2-propyl) phenyl, 4-chloro- 3-amidinophenyl , 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl) henyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) henyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, 6- (2-amino-2-propyl)pyrid-2-yl; A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and,
B is selected from the group: 2-CF3-phenyl , 2-
(aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl, 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-1-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l,2,3 -triazolyl .
[10] In a still further preferred embodiment, the present invention provides a novel compound of formula la.
[11] In another still further preferred embodiment, the present invention provides a novel compound of formula lb.
[12] In another even more preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
D is selected from C ( =NR8) NR7R9 , C(0)NR7R8, NR7R8, and CH2NR7R8 ;
E is phenyl substituted with R or pyridyl substituted with R;
R is selected from H, Cl, F, OR3, CH3 CH2CH3, 0CF3, and CF3;
Z is selected from C(O), CH2C(0), C(0)CH2, NHC(O), and C(0)NH, provided that Z does not form a N-N bond with group A; Rla and Rlb are, at each occurrence, independently selected from H, -(CH2)r-R1'» NCH2R1", OCH2R1", SCH2R1", N(CH2)2(CH2)tR1', 0(CH2)2(CH2)tR1', and S (CH2 ) 2 (CH2 ) tR1' ;
Rlc is selected from H, -(CH2)q-R1', Cι_3 alkyl, C(0)R2c, (CF2)rC02R2c, and C(0)NR2R2a;
R1', at each occurrence, is selected from H, Cχ_3 alkyl, halo, (CF2)rCF3, OR2, NR2R2a, C(0)R2c, (CF2) rC02R2c, S(0)pR2b, NR (CH2)r0R2, NR2C(0)R2b, NR2C(0)2R2b, C(0)NR2Ra, S02NR2R2 , and NR2S02R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl , pyrazolyl , and imidazolyl ;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from CH2, -CR2 (CR2R2b) (CH2) t-, -C(O)-, -C(=NR)-, -CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2- , -NR2-, and 0;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl , piperidinyl , piperazinyl , pyridyl , pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl, 1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl;
R4, at each occurrence, is selected from =0, OH, Cl, F, C1-4 alkyl, (CH2) rNR2Ra, (CH2) rC (0)R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
Ra, at each occurrence, is selected from =0, OH, Cl, F, Cι_4 alkyl, (CH2) rNR2Ra, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S0 -Cι_ alkyl, NR2S02R5, S(0)PR5, (CF2)rCF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , C]__6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, =0, OH, OR2, Cl, F, CH3, CN, N02, (CH2)rNR2R2 , (CH2) rC (0) R2b, NR2C(0)R2b, CH(=NH)NH2/ NHC(=NH)NH2, and S02NR2R2a;
R7, at each occurrence, is selected from H, OH, Cχ-6 alkyl, Cι_6 alkylcarbonyl , Cχ_6 alkoxy, Cι_4 alkoxycarbonyl, benzyl, Cs-io aryloxy, Cδ-io aryloxycarbonyl , C6-10 arylmethylcarbonyl, C1-.4 alkylcarbonyloxy C1-.4 alkoxycarbonyl, Cδ-io arylcarbonyloxy Cχ_4 alkoxycarbonyl, C1-6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cχ_4 alkoxycarbonyl ;
R8, at each occurrence, is selected from H, Cι_6 alkyl and benzyl ; and
alternatively, R7 and R8 combine to form a morpholino group; and,
R9, at each occurrence, is selected from H, Cι_6 alkyl and benzyl . [13] In a another further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
R is selected from H, Cl, F, 0CH3, CH3, OCF3, and CF3 ;
Z is selected from a C(0)CH2 and C(0)NH, provided that Z does not form a N-N bond with group A;
Rla, at each occurrence, is selected from H, CH3, CH2CH3 , Cl, F, CF3, OCH3, NR2R2 , S(0)pR2b, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2a, and S02NR2R2a;
Rlb is selected from H, CH3, CH2CH3 , Cl, F, CF3, OCH3 , NR2R2a, S(0)pR2b, CH2S(0)pR2 , CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2 , and S0NR2R2a;
RIC is selected from H, CH3 , CH2CH3, CF3, CH2S(0)pR2b,
CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, and C(0)NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
B is selected from: Y and X-Y;
X is selected from CH2, -CR2 (CR2R2b) -, -C(O)-, -C(=NR)-,
-CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2- , -NR2-, and O;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl , thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl,
1,2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2 , 5-triazolyl, and 1, 3 , 4-triazolyl;
R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl ;
R2a, at each occurrence, is selected from H, CF3 , CH3, benzyl, and phenyl ;
R2b, at each occurrence, is selected from CF3, OCH3, CH3, benzyl , and phenyl ;
R2c, at each occurrence, is selected from CF3, OH, OCH3 , CH3, benzyl, and phenyl;
alternatively, R2 and Ra combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3 , at each occurrence, is selected from H, CH3, CH2CH3 , and phenyl ;
R3a, at each occurrence, is selected from H, CH3, CH2CH3, and phenyl ; R4, at each occurrence, is selected from OH, Cl, F, CH3,
CH2CH3, NR2R2a, CH2NR2R2 , C(0)R2b, NR2C(0)R2b, C(0)NR2R2a, and CF3;
R4a, at each occurrence, is selected from OH, Cl, F, CH3,
CH2CH3, NR2R2a, CH2NR2R2 , C(0)R2b, C(0)NR2Ra, S02NR2R2a, S(0)pR5, CF3, and l-CF3-tetrazol-2-yl;
R5 , at each occurrence, is selected from CF3, Cι_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 1 R6;
R6, at each occurrence, is selected from H, OH, OCH3 , Cl, F, CH3, CN, N02, NR2R2a, CH2NR2Ra, and S0NR2R2a;
R7, at each occurrence, is selected from H, OH, C1-3 alkyl, Cι_3 alkylcarbonyl , Cχ_3 alkoxy, C1-.4 alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl, benzylcarbonyl , C1-.4 alkylcarbonyloxy Cχ_4 alkoxycarbonyl, phenylcarbonyloxy Cι_4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C1-.4 alkoxycarbonyl;
R8 , at each occurrence, is selected from H, CH3 , and benzyl,- and,
alternatively, R7 and R8 combine to form a morpholino group;
R9 , at each occurrence, is selected from H, CH3 , and benzyl.
[14] In a another still further preferred embodiment, the present invention provides novel compounds of formulae la-lb, wherein;
Rla, at each occurrence, is selected from H, CH3, CH2CH3, Cl, F, CF3, OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2 , and S02NR2R2a; Rib Ξ selected from H, CH3 , CHCH3 , Cl, F, CF3 , OCH3 , NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S (0) pR2b, C(0)R2b, CH2C(0)R2b, and S02NR2R2a;
Rlc is selected from H, CH3, CH2CH3 , CF3 , C(0)NR2R2a,
CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2b, and CH2C(0)R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, and pyrimidyl;
B is selected from: Y and X-Y;
X is selected from -C(O)- and O;
Y is NR2R2a, provided that X-Y do not form a 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ;
R2, at each occurrence, is selected from H, CF3 , CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3 , CH3, benzyl, and phenyl;
R2b, at each occurrence, is selected from CF3, OCH3, CH3, benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3 , CH3, benzyl, and phenyl;
alternatively, R2 and R2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino; R4, at each occurrence, is selected from Cl, F, CH3 , NR2R2a, and CF3;
Ra, at each occurrence, is selected from Cl, F, CH3, S0NR2R2a, S(0)pR5, and CF3 ; and,
R5, at each occurrence, is selected from CF3 and CH3.
[15] Specifically preferred compounds of the present invention are selected from the group:
1- (3-amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen-4- yl) -aminocarbony1] -3-trifluoromethyl-pyrazoline; and,
1- (3-aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline;
and pharmaceutically acceptable salts thereof.
In a second embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof.
In a third embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt form thereof .
DEFINITIONS The compounds herein described may have asymmetric centers . Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms . It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. The term "substituted, " as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. When any variable (e.g., R>) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R6, then said group may optionally be substituted with up to two R6 groups and R6 at each occurrence is selected independently from the definition of R6. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "Cι_6 alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl; "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like.
"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like. As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4. O]bicyclodecane (decalin) , [2.2.2] bicyclooctane, fluorenyl , phenyl , naphthyl , indanyl , adamantyl, or tetrahydronaphthyl (tetralin) . As used herein, the term "heterocycle" or "heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which is saturated partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, 0 and S. It is preferred that the total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
Examples of heterocycles include, but are not limited to, lH-indazole, 2-pyrrolidonyl, 2H, 6H-1, 5, 2-dithiazinyl, 2H- pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H- quinolizinyl, 6H-1, 2 , 5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl , benzothiofuranyl, benzothiophenyl , benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aff-carbazolyl , β-carbolinyl , chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H- 1,5,2-dithiazinyl , dihydrofuro [2,3 -b] tetrahydrofuran, furanyl , furazanyl, imidazolidinyl , imidazolinyl, imidazolyl, 1H- indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl , isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl , octahydroisoquinolinyl, oxadiazolyl, 1, 2 , 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1,2,5- oxadiazolyl, 1, 3 , 4-oxadiazolyl, oxazolidinyl . , oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl , phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl , quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl , tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1, 2,5- thiadiazinyl, 1, 2 , 3-thiadiazolyl, 1, 2 , 4-thiadiazolyl, 1,2,5- thiadiazolyl, 1, 3 , 4-thiadiazolyl, thianthrenyl , thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1, 2 , 3 -triazolyl, 1, 2 , 4-triazolyl, 1, 2 , 5-triazolyl, 1, 3 , 4-triazolyl, xanthenyl . Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinoyl . Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio .
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic , phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like .
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical Sciences, 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I) , and the like. Preferred prodrugs are amidine prodrugs wherein D is C(=NR7)NH2 or its tautomer C(=NH)NHR7 and R7 is selected from OH, Cι-4 alkoxy, Cβ-io aryloxy, C1-.4 alkoxycarbonyl, C6_ιo aryloxycarbonyl , Cβ-io arylmethylcarbonyl , C1-.4 alkylcarbonyloxy Cχ_4 alkoxycarbonyl, and C6-10 arylcarbonyloxy C1-4 alkoxycarbonyl. More preferred prodrugs are where R7 is OH, methoxy, ethoxy, benzyloxycarbonyl, methoxycarbonyl , and methylcarbonyloxymethoxycarbonyl .
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
SYNTHESIS The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis . The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In Organic Synthesis, Wiley and Sons, 1991) . All references cited herein are hereby incorporated in their entirety herein by reference.
Pyrazolines of this invention can be easily prepared via [3+2] cycloaddition of bromo or chloro hydrazone with an appropriate acrylate according to the methodology described by Tewari R. S. and Parihar Tetrahedron 1983, 39, 129-136, or Krayushkin, M. M. et . al Izv. Akad. Nauk, Ser . Khim . 199 A , 1 , 114-117.
Figure imgf000031_0001
Pyrazoline 5-esters can also be prepared by the treatment of an appropriately substituted hydrazone with lead tetraacetate and an appropriate acrylate in a THF/benzene solvent system according to the procedure of Sasaki T, et. al. Bull . Chem Soc . Jpn . 1970, 43 , 1254.
Figure imgf000031_0002
Another method of obtaining pyrazoline 5-esters is the condensation of an appropriate phenyl or heteroaryl hydrazine with an approptiate 2-oxoglutaconate according to Blitzke, T. et. al. J. Prakt . Chem . 1993, 335 (8) , 683.
Figure imgf000032_0001
Alternatively the pyrazoline ester can be prepared by treatment of a diazo-trifluoromethyl derivative with excess acrylate or acrolein in the presence of excess pyridine (Doyle, M. 0. et . al . J. Heterocyclic Chem. 1983, 20, 943) .
Figure imgf000032_0002
Cycloadditions as described above but with di-substituted olefins should result in the formation of regio-adducts which can be easily separated by standard chromatographic techniques .
Figure imgf000032_0003
It is understood by those in the art of organic synthesis that such cycloadditions can also be carried out with a wide variety of electron withdrawing olefins with functionalities such as nitro, sulfonyl, sulfonamido, nitrile, phosphate etc. These in turn can be derivatized to appropriate compounds of the present invention. The pyrazoline carboxyesters obtained via any of the above mentioned methodologies can be converted to the amide derivatives via the acid, acid chloride coupling methodlogies or a direct Weinreb (trimethylaluminum, aniline in dichloromethane) coupling technique known to those in the art of organic synthesis . A variety of anilines or amines can be coupled via these methodologies to afford the desired compounds .
Figure imgf000033_0001
Alternatively the ester can be hydrolysed and converted to an amino functionality via the Curtius rearrangement. This in turn can be derivatised to obtain an amido, sulfonamido or urea derivative.
Figure imgf000034_0001
Pyrazolines wherein s is other than 0 can be prepared by alkylation of an appropriate pyrazoline.
Figure imgf000034_0002
The electrophile can consist of simple alkyl halides to heteroaryl alkyl halides . Some of the heteroaryl alkyl groups can include pyridyl, pyrimidyl, imidazolyl etc.
In cases wherein D is a nitrile can be further converted to an amidine functionality via the standard Pinner-amidine reaction sequence known to those in the art or can be converted to the benzylamine via reduction in an acidic media or can be converted to the secondary and tertiary amine via the DIBAH/MeMgCl or MeMgBr/CeCl3 methodologies outlined below.
Figure imgf000035_0001
Compounds wherein D is a nitro can be reduced under catalytic Pd/C/MeOH techniques or SnCl2/EtOAc or Zn/AcOH conditions to afford the desired amino derivatives. Enantiomers of the pyrazolines can be easily obtained either via lipase hydrolysis of its esters or resolution with common chiral bases known to those in the art .
1, 2 , 3-Triazolines can be synthesized via the cycloaddition methodology however in this case the dipole is an aryl azide and the dipolarophile is a variety of olefins bearing an electron withdrawing group such as an ester, amide or sulfonamide. + regioisomer
Figure imgf000036_0001
1, 2 , 4-Triazolines can be prepared via the methods of Sandhy J. S. et. al . Heterocycles 1985, 23 (5) , 1143, and Heterocycles 1985, 23 (5) , 1123, by the method described in the scheme below.
Figure imgf000036_0002
The triazoline esters can then subjected to the standard coupling procedures discussed above to afford the desired amide analogs. These can then further modified to the prepare compounds of the present invention.
Compounds of the present invention wherein AB is a biphenylamine or similar amine may be prepared as shown in the following scheme. 4-Bromoaniline can be protected as Boc- derivative and coupled to a phenylboronic acid under Suzuki conditions (Bioorg. Med. Chem . Lett . 1994, 189) . Deprotection with TFA provides the aminobiphenyl compound. Other similar amines wherein A and/or B are heterocycles can be prepared by the same method using appropiately substituted boronic acids and arylbromide. The bromoaniline can also be linked to the core ring structures first as described above, and then undergo a Suzuki reaction to give the desired product .
Figure imgf000037_0001
Compounds of the present invention wherein A-B is A-X-Y can be prepared like the piperazine derivative shown below.
Figure imgf000037_0002
The following scheme shows how one can couple cyclic groups wherein X=NH, O, or S.
reduction
Figure imgf000037_0003
Halo Base, DMF
Figure imgf000037_0004
X = NH, 0, S
When B is defined as X-Y, the following description applies . Groups A and B are available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis. The required reactive functional groups appended to analogs of A and B are also available either through commercial sources, known in the literature or readily synthesized by the adaptation of standard procedures known to practioners skilled in the art of organic synthesis . In the tables that follow the chemistry required to effect the coupling of A to B is outlined.
Table A: Preparation of Amide, Ester, Urea,
Figure imgf000038_0001
Figure imgf000039_0001
The chemistry of Table A can be carried out in aprotic solvents such as a chlorocarbon, pyridine, benzene or toluene, at temperatures ranging from -20 C to the reflux point of the solvent and with or without a trialkylamine base. Table B: Preparation of ketone linkages between A and
B.
Figure imgf000040_0001
The coupling chemistry of Table B can be carried out by a variety of methods . The Grignard reagent required for Y is prepared from a halogen analog of Y in dry ether, dimethoxyethane or tetrahydrofuran at 0 C to the reflux point of the solvent. This Grignard reagent can be reacted directly under very controlled conditions, that is low temeprature (- 20 C or lower) and with a large excess of acid chloride or with catalytic or stoichiometric copper bromide*dimethyl sulfide complex in dimethyl sulfide as a solvent or with a variant thereof. Other methods available include transforming the Grignard reagent to the cadmium reagent and coupling according to the procedure of Carson and Prout (Org. Syn. Col. Vol. 3 (1955) 601) or a coupling mediated by Fe(acac)3 according to Fiandanese et al . (Tetrahedron Lett., (1984) 4805) , or a coupling mediated by manganese (II) catalysis (Cahiez and Laboue, Tetrahedron Lett., 33(31), (1992) 4437).
Table C: Preparation of ether and thioether linkages between A and B
Figure imgf000041_0001
The ether and thioether linkages of Table C can be prepared by reacting the two components in a polar aprotic solvent such as acetone, dimethylforma ide or dimethylsulfoxide in the presence of a base such as potassium carbonate, sodium hydride or potassium t-butoxide at temperature ranging from ambient temperature to the reflux point of the solvent used.
Table D: Preparation of -SO- and -S02- linkages from
Figure imgf000041_0002
The thioethers of Table C serve as a convenient starting material for the preparation of the sulfoxide and sulfone analogs of Table D. A combination of wet alumina and oxone can provide a reliable reagent for the oxidation of the thioether to the sulfoxide while m-chloroperbenzoic acid oxidation will give the sulfone.
Table E: Methods of Preparing Group E
Rxn D is to be then a transformation that may be used is
NH2
-CN -C ( =NH) NH2 i) HC1 MeOH /
:N ii) NH3OAc, MeOH NH
-CN -CH2NH2 LiAlH,
:N ■CH2NH2
Figure imgf000042_0001
-C02H -CH2NH2 i) iBuOC(O)Cl
Figure imgf000042_0002
-C02H -NH2 i) iBuOC(O)Cl
NMM, THF then NaN3 and heat
■NH2 ii) tBuOH, reflux OH ϋi)HCl, Et2O
In Table E several methods of transforming a functional group Q into group D of Formula 1 are shown. While not all possible functional groups for Q and D are listed and the synthetic methods suggested are not comprehensive. Table E is meant to illustrate strategies and transformations available to a practitioner skilled in the art of organic synthesis for preparing compounds of Formula 1. In reaction 1 of Table E the transformation of a nitrile into an amidine by the Pinner methodology is shown; in reaction 2 the direct reduction of a nitrile by a hydride reducing agent to a methylene amine is illustrated. In reaction 3, the utility of a carboxylic acid, which may be readily derived from its ester or a nitrile if necessary, in the preparation of a methylene amine is shown. This synthetic route is exceptionally flexible because of the several stable intermediates prepared en route to the final product. As outlined, formation of an activated analog, such as the mixed anhydride, allows for the mild reduction of the acid to the methylene alcohol, this may in turn be transformed into a leaving group by sulfonylation or halogenation or protected with a suitable protecting group to be transformed later in the synthesis as the chemistry demands . Once the methylene alcohol is so activated, displacement by an efficient nitrogen nucleophile, such as azide anion, can again provide another suitably stable analog, -the methylene azide- which may be used as a protected form of the methylene amine or transformed directly into the methylene amine group by reduction. Reaction 4 addresses the problem of appending the amine functionality directly through a bond to group E of Formula 1. Once again, the carboxylic acid provides a convenient eπtre into this selection for group D. The well- know Curtius rearrangement is illustrated here; an activated acid analog can be used to form an acyl azide which upon thermal decomposition is rearranged to the corresponding isocyanate. The isocyanate intermediate may then be captured as a stable carbamate by the addition of a suitable alcohol and further heating. This carbamate can be used as a stable protecting group for the amine or cleaved directly to the desired D. Alternatively, it may be convenient to quench the isocyanate intermediate with water to give the amine directly. One diastereomer of a compound of Formula I may display superior activity compared with the others. Thus, the following stereochemistries are considered to be a part of the present invention.
Figure imgf000043_0001
Iai Ia2
Figure imgf000044_0001
Ibi Ib2
Figure imgf000044_0002
ICi IC2
Figure imgf000044_0003
When required, separation of the racemic material can be achieved by HPLC using a chiral column or by a resolution using a resolving agent such as camphonic chloride as in Steven D. Young, et al, Antimicrobial Agents and Chemotheraphy, 1995, 2602-2605. A chiral compound of Formula I may also be directly synthesized using a chiral catalyst or a chiral ligand, e.g., Andrew S. Thompson, et al, Tet. lett. 1995, 36, 8937-8940) .
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES Examples 1 and 2
1- (3 -Amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1']- biphen-4-yl) -aminocarbonyl] -3-trif luoromethyl- pyrazoline and 1- (3-aminomethylphenyl) -5- [[ (2 ' - methylsulfonyl- [1, 1 • ] -biphen-4-yl) -aminocarbonyl] -3- trif luoromethyl-pyrazoline
Part A: To a methanolic solution containing meta-cyanophenyl- hydrazine (2 g, 15.03 mol) was added trifluoromethylacetaldehyde hydrate (1.74 g, 15.03 mmol) . The reaction mixture was heated to gentle reflux overnight.
Methanol was stripped off to afford yellow crystals of pure hydrazone (2.99g, 93%) . 1HNMR (CDCl3)δ: 10.10 (bs, 1H) , 7.33
(m, 2H) , 7.10 (m, 2H) ppm; ESI (-ve) mass spectrum analysis m/z (relative intensity) 212 (M-H, 100) .
Part B: NCS (1.02 g, 7.69 mmol) was added to a DMF (25 mL) solution of the compound prepared in part A (1.64 g, 7.69 mmol) . The reaction mixture was stirred at room temperature over night, quenched with water (500 mL) and organics extracted with ethyl acetate (2x100 mL) dried (MgS04) and evaporated to a reddish brown oil . The oil was redissolved in chloroform (25 mL) and to this solution was added ethyl acrylate (10 mL) followed by slow addition of triethylamine (0.81 mL, 5.75 mmoL) . The reaction mixture was refluxed for 18h cooled and quenched with dil. hydrochloric acid (IN, 20 mL) . The organic layer was separated and evaporated to an oil. Chromatography on silica gel (7:3, Hexane:ethylacetate) afforded a colorless oil which solidified on standing (1.5 g, 62%). 1HNMR(CDCl3)δ: 7.40-7.22 (m, 4H) , 4.89 (dd, J = 6.2 and 13.4Hz, 1H) , 4.24 (q, 2H) , 3.63-3.50 (dd, J = 1.9 and 13.2Hz, 1H) , 3.38 (dd, J = 1.9 and 14Hz, 1H) , 1.23 (t, 3H) ppm; ESI mass spectrum analysis m/z (relative intensity) 312 (M+H, 100) . Part C: The product from part B was treated with 2 ' - methylsulfonyl-4-amino- [1, 1' ]biphenyl under Weinreb conditions (trimethylaluminum in dichloromethane) to afford pure coupled product (oil) after silica gel column chromatography
(hexane: ethyl acetate 7:3). 1HNMR (CDC13 ) δ: 8.40 (bs, IH) , 8.17
(dd, J = 1.1 and 7.8Hz, IH) , 7.65-7.25 ( , 11H) , 4.90 (m, IH) ,
3.78 (m, IH) , 3.38 (dd, J = 1.5 and 8.1Hz, IH) , 2.69 s, 3H) ;
ESI (-ve) mass spectrum analysis m/z (rel. intensity) 511 (M- H, 100) .
Part D: The product from part C was subjected to the Pinner amidine reaction sequence (HCl/MeOH followed by ammonium carbonate in methanol) , purified via standard HPLC purification, lyophilization to afford (40% yield) of Example 1 as colorless crystals. XHΝMR (DMS06) δ: 9.36 (bs, 1.5H), 9.00
(bs, 1.5Hz), 8.06 (d, J = 7.7Hz, IH) , 7.53-7.78 (m, 6H) , 7.35 (d, J = 8.1Hz, 3H) , 7.27 (d, J = 8.0Hz, IH) , 7.17 (d, J = 8.5Hz, IH) , 5.33 (dd, J = 6.2 and 13.2Hz, IH) , 3.76 (t, IH) , 3.40 (d, J = 3.1Hz, IH) , 2.84(s, 3H) ppm; ESI (+ve) mass spectum analysis m/z (relative intensity) 530 (M+H, 100) .
Additionally, the compound form Part C was subjected to reduction using 10% Pd/C in an acidic medium (methanol/acetic acid) . Purification via standard HPLC techniques and lyophilization afforded the benzylamine (10% yield) . 1HNMR(DMS06)δ: 8.07 (bs, 2H) , 8.01 (d, J = 8Hz, IH) , 7.70 (m,
IH) , 7.59 (m, 3H) , 7.28 (m, 4H) , 6.95 (d, J = 8Hz, IH) , 6.83 (dd, J = 1/5 and 8Hz, IH) , 6.40 (bs, 2H) , 5.22 (dd, J = 6.5 and 13Hz, IH) , 4.00 (m, IH) , 3.71 (m, IH) , 3.34 (dd, J = 1.5 and 8Hz, IH) , 2.84 (s, 3H) ppm; ESI mass spectrum analysis m/z (relative intensity) 517 (M+H, 100) .
The following tables contain representative examples of the present invention. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, in Table 1, example 1 is intended to be paired with each of formulae a-ttt and in Table 2, example 1 is intended to be paired with each of formulae a-ss .
The following groups are intended for group A in the following tables .
Figure imgf000047_0001
2-pyrιdyl 3-pyrιdyl 2-pyrιmιdyl
»^Q-< 3 -™-\ )-B _H - -B
5-pyrιmιdyl 2-CI-phenyl 2-F-phenyl
Figure imgf000047_0002
2,6-dιF-phenyl
Table 1
Figure imgf000048_0001
' j
Figure imgf000049_0001
m
Figure imgf000049_0002
Figure imgf000050_0001
w
Figure imgf000050_0002
aa bb
Figure imgf000051_0001
hh gg
Figure imgf000051_0002
kk
Figure imgf000052_0001
oo PP qq
Figure imgf000052_0002
tt rr ss
Figure imgf000053_0001
xx zz yy
Figure imgf000053_0002
Figure imgf000054_0001
ggg hhh
Figure imgf000054_0002
JJJ kkk
Figure imgf000055_0001
m m
Figure imgf000055_0002
sss ttt
# l i e B
CH3 phenyl 2- (aminosulfonyl ) phenyl
CH3 phenyl 2 - (methylammosulf onyl ) phenyl
CH3 phenyl 1 -pyrr o 1 idinocarbony 1
CH3 phenyl 2- (methylsulfonyl ) phenyl
CH3 phenyl 4 -morpholino
CH3 phenyl 2- ( 1 ' -CF3 -tetrazol -2 -yl ) phenyl
CH3 phenyl 4-morpholinocarbonyl
CH3 phenyl 2-methyl-l-imidazolyl
CH3 phenyl 5 -methyl -1- imidazolyl
CH3 phenyl 2 -methylsulfonyl-1- imidazolyl
CH3 2-pyridyl 2 - ( aminosulfonyl ) phenyl
CH3 2-pyridyl 2 - (methylammosulf onyl ) phenyl
CH3 2-pyridyl 1-pyrrolidinocarbonyl
CH3 2-pyridyl 2- (methylsulfonyl ) phenyl
CH3 2-pyridyl 4 -morpholino
CH3 2-pyridyl 2- ( 1 ' -CF3 -tetrazol -2 -yl) phenyl
CH3 2-pyridyl 4 -morpholinocarbonyl CH3 2-pyridyl 2-methyl-l-imidazolyl
CH3 2-pyridyl 5-methyl-1-imidazolyl
CH3 2-pyridyl 2-methylsulfonyl-1-imidazolyl
CH3 3-pyridyl 2- (aminosulfonyl)phenyl
CH3 3-pyridyl 2- (methylammosulfonyl) phenyl
CH3 3-pyridyl 1-pyrro1idinocarbony1
CH3 3-pyridyl 2- (methylsulfonyl)phenyl
CH3 3-pyridyl 4-morpholino
CH3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl
CH3 3-pyridyl 4-morpholinocarbonyl
CH3 3-pyridyl 2-methyl-l-imidazolyl
CH3 3-pyridyl 5-methyl-l-imidazolyl
CH3 3-pyridyl 2-methylsulfonyl-1-imidazolyl
CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl
CH3 2-pyrimidyl 2- (methylammosulfonyl)phenyl
CH3 2-pyrimidyl 1-pyrrolidinocarbonyl
CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
CH3 2-pyrimidyl 4-morpholino
CH3 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
CH3 2-pyrimidyl 4-morpholinocarbonyl
CH3 2-pyrimidyl 2-methyl-l-imidazolyl
CH3 2-pyrimidyl 5-methyl-l-imidazolyl
CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
CH3 5-pyrimidyl 2- (methylammosulfonyl) phenyl
CH3 5-pyrimidyl 1-pyrro1idinocarbony1
CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl
CH3 5-pyrimidyl 4-morpholino
CH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
CH3 5-pyrimidyl 4-morpho1inocarbony1
CH3 5-pyrimidyl 2-methyl-l-imidazolyl
CH3 5-pyrimidyl 5-methyl-l-imidazolyl
CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
CH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl
CH3 2-Cl-phenyl 2- (methylammosulfonyl)phenyl
CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
CH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl CH3 2-Cl-phenyl 4-morpho1ino
CH3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
CH3 2-Cl-phenyl 4-morpholinocarbonyl
CH3 2-Cl-phenyl 2-methyl-l-imidazolyl
CH3 2-Cl-phenyl 5-methyl-l-imidazolyl
CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
CH3 2-F-phenyl 2- (aminosulfonyl) phenyl
CH3 2-F-phenyl 2- (methylammosulfonyl ) phenyl
CH3 2-F-phenyl 1-pyrrolidinocarbonyl
CH3 2-F-phenyl 2- (methylsulfonyl) phenyl
CH3 2-F-phenyl 4-morpholino
CH3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl
CH3 2-F-phenyl 4-morpholinocarbonyl
CH3 2-F-phenyl 2-methyl-l-imidazolyl
CH3 2-F-phenyl 5-methyl-l-imidazolyl
CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
CH3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
CH3 2, 6-diF-phenyl 2- (methylammosulfonyl) phenyl
CH3 2, 6-diF-phenyl 1-pyrro1idinocarbony1
CH3 2, 6-diF-phenyl 2- (methylsulfonyl ) phenyl
CH3 2, 6-diF-phenyl 4-morpholino
CH3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
CH3 2,6-diF-phenyl 4-morpholinocarbonyl
CH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl
CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
CH3 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
CH2CH3 phenyl 2- (aminosulfonyl) phenyl
CH2CH3 phenyl 2- (methylaminosulfonyl) phenyl
CH2CH3 phenyl 1-pyrrolidinocarbonyl
CH2CH3 phenyl 2- (methylsulfonyl) phenyl
CH2CH3 phenyl 4-morpholino
CH2CH3 phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl
CH2CH3 phenyl 4-morpho1inocarbony1
CH2CH3 phenyl 2-methyl-l-imidazolyl
CH2CH3 phenyl 5-methyl-l-imidazolyl
CH2CH3 phenyl 2-methylsulfonyl-l-imidazolyl
CH2CH3 2-pyridyl 2- (aminosulfonyl) phenyl 92 CH2CH3 2-pyridyl 2- (methylaminosulfonyl)phenyl
93 CH2CH3 2-pyridyl 1-pyrrolidinocarbonyl
94 CH2CH3 2-pyridyl 2- (methylsulfonyl)phenyl
95 CH2CH3 2-pyridyl 4-morpho1ino
96 CH2CH3 2-pyridyl 2- (l'-CF3-tetrazol-2-yl)phenyl
97 CH2CH3 2-pyridyl 4-morpholinocarbonyl
98 CH2CH3 2-pyridyl 2-methyl-l-imidazolyl
99 CH2CH3 2-pyridyl 5-methyl-l-imidazolyl
100 CH2CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
101 CH2CH3 3-pyridyl 2- (aminosulfonyl)phenyl
102 CH2CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
103 CH2CH3 3-pyridyl 1-pyrrolidinocarbonyl
104 CH2CH3 3-pyridyl 2- (methylsulfonyl) phenyl
105 CH2CH3 3-pyridyl 4-morpho1ino
106 CHCH3 3-pyridyl 2-(l' -CF3-tetrazol-2-yl)phenyl
107 CH2CH3 3-pyridyl 4-morpholinocarbonyl
108 CH2CH3 3-pyridyl 2-methyl-l-imidazolyl
109 CH2CH3 3-pyridyl 5-methyl-l-imidazolyl
110 CH2CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
111 CH2CH3 2-pyrimidyl 2- (aminosulfonyl)phenyl 112 CH2CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 113 CH2CH3 2-pyrimidyl 1-pyrro1idinocarbony1 114 CH2CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl 115 CH2CH3 2-pyrimidyl 4-morpholino 116 CHCH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 117 CH2CH3 2-pyrimidyl 4-morpho1inocarbony1 118 CH2CH3 2-pyrimidyl 2-methyl-l-imidazolyl 119 CH2CH3 2-pyrimidyl 5-methyl-l-imidazolyl 120 CH2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
121 CH2CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl 122 CH2CH3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 123 CH2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 124 CH2CH3 5-pyrimidyl 2- (methylsulfonyl)phenyl 125 CH2CH3 5-pyrimidyl 4-morpho1ino 126 CH2CH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 127 CH2CH3 5-pyrimidyl 4-morpholinocarbonyl 128 CH2CH3 5-pyrimidyl 2-methyl-l-imidazolyl 129 CH2CH3 5-pyrimidyl 5-methyl-1-imidazolyl 130 CH2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
131 CH2CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 132 CH2CH3 2-Cl-phenyl 2- (methylaminosulfonyl ) phenyl 133 CH2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 134 CH2CH3 2 -Cl-phenyl 2- (methylsulfonyl ) henyl 135 CH2CH3 2-Cl-phenyl 4-morpholino 136 CHCH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 137 CH2CH3 2-Cl-phenyl 4-morpholinocarbonyl 138 CH2CH3 2-Cl-phenyl 2-methyl-l-imidazolyl 139 CH2CH3 2-Cl-phenyl 5-methyl-l-imidazolyl 140 CH2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
141 CH2CH3 2 -F-phenyl 2- (aminosulfonyl ) phenyl 142 CH2CH3 2 -F-phenyl 2- (methylaminosulfonyl ) phenyl 143 CH2CH3 2-F-phenyl 1-pyrrolidinocarbonyl 144 CH2CH3 2-F-phenyl 2- (methylsulfonyl ) phenyl 145 CH2CH3 2-F-phenyl 4-morpholino 146 CH2CH3 2-F-phenyl 2- (l'-CF3-tetrazol-2-yl) phenyl 147 CH2CH3 2-F-phenyl 4-morpho1inocarbony1 148 CH2CH3 2-F-phenyl 2-methyl-1-imidazolyl 149 CH2CH3 2-F-phenyl 5-methyl-l-imidazolyl 150 CH2CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
151 CH2CH3 2, , 6-diF-phenyl 2- (aminosulfonyl) phenyl
152 CH2CH3 2, , 6-diF-phenyl 2 - (methylaminosulfonyl ) phenyl
153 CH2CH3 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl
154 CH2CH3 2, , 6-diF-phenyl 2- (methylsulfonyl ) phenyl
155 CH2CH3 2, .6-diF-phenyl 4-morpholino
156 CH2CH3 2, , 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl
157 CH2CH3 2, , 6-diF-phenyl 4-morpho1inocarbony1
158 CH2CH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl
159 CH2CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
160 CH2CH 2, 6-diF-ohenyl 2-methylsulfonyl-l-imidazolyl
161 CF3 phenyl 2- (aminosulfonyl ) phenyl 162 CF3 phenyl 2- (methylaminosulfonyl) phenyl 163 CF3 phenyl 1-pyrrolidinocarbonyl 164 CF3 phenyl 2- (methylsulfonyl ) phenyl 165 CF3 phenyl 4-morpholino 166 CF3 phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 167 CF3 phenyl 4-morpholinocarbonyl 168 CF3 phenyl 2-methyl-l-imidazolyl 169 CF3 phenyl 5-methyl-l-imidazolyl 170 CF3 phenyl 2-methylsulfonyl-l-imidazolyl
171 CF3 2-pyridyl 2- (aminosulfonyl) phenyl
172 CF3 2-pyridyl 2- (methylaminosulfonyl) phenyl
173 CF3 2-pyridyl 1-pyrrolidinocarbonyl
174 CF3 2-pyridyl 2- (methylsulfonyl) phenyl
175 CF3 2-pyridyl 4-morpholino
176 CF3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
177 CF3 2-pyridyl 4-morpholinocarbonyl
178 CF3 2-pyridyl 2-methyl-l-imidazolyl
179 CF3 2-pyridyl 5-methyl-l-imidazolyl
180 CF3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
181 CF3 3-pyridyl 2- (aminosulfonyl) phenyl
182 CF3 3-pyridyl 2- (methylaminosulfonyl) phenyl
183 CF3 3-pyridyl 1-pyrrolidinocarbonyl
184 CF3 3-pyridyl 2- (methylsulfonyl) phenyl
185 CF3 3-pyridyl 4-morpholino
186 CF3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl
187 CF3 3-pyridyl 4-morpholinocarbonyl
188 CF3 3-pyridyl 2-methyl-l-imidazolyl
189 CF3 3-pyridyl 5-methyl-l-imidazolyl
190 CF3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
191 CF3 2-pyrimidyl 2- (aminosulfonyl) phenyl
192 CF3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
193 CF3 2-pyrimidyl 1-pyrrolidinocarbonyl
194 CF3 2-pyrimidyl 2- (methylsulfonyl) phenyl
195 CF3 2-pyrimidyl 4-morpho1ino
196 CF3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl
197 CF3 2-pyrimidyl 4-morpholinocarbony1
198 CF3 2-pyrimidyl 2-methyl-l-imidazolyl
199 CF3 2-pyrimidyl 5-methyl-l-imidazolyl
200 CF3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
201 CF3 5-pyrimidyl 2- (aminosulfonyl) henyl
202 CF3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 203 CF3 5-pyrimidyl 1-pyrrolidinocarbonyl
204 CF3 5-pyrimidyl 2- (methylsulfonyl ) phenyl
205 CF3 5-pyrimidyl 4-morpholino
206 CF3 5-pyrimidyl 2- ( l ' -CF3 -tetrazol-2-yl ) phenyl
207 CF3 5-pyrimidyl 4-morpholinocarbonyl
208 CF3 5-pyrimidyl 2-methyl-l-imidazolyl
209 CF3 5-pyrimidyl 5-methyl-l-imidazolyl
210 CF3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
211 CF3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
212 CF3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
213 CF3 2-Cl-phenyl 1-pyrro1idinocarbony1
214 CF3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
215 CF3 2-Cl-phenyl 4-morpholino
216 CF3 2-Cl-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl
217 CF3 2-Cl-phenyl 4-morpholinocarbonyl
218 CF3 2-Cl-phenyl 2-methyl-l-imidazolyl
219 CF3 2-Cl-phenyl 5-methyl-l-imidazolyl
220 CF3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
221 CF3 2-F-phenyl 2- (aminosulfonyl)phenyl
222 CF3 2-F-phenyl 2- (methylaminosulfonyl) phenyl
223 CF3 2-F-phenyl 1-pyrro1idinocarbony1
224 CF3 2-F-phenyl 2- (methylsulfonyl) phenyl
225 CF3 2-F-phenyl 4-morpho1ino
226 CF3 2-F-phenyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl
227 CF3 2-F-phenyl 4-morpholinocarbonyl
228 CF3 2-F-phenyl 2-methyl-1-imidazolyl
229 CF3 2-F-phenyl 5-methyl-l-imidazolyl
230 CF3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
231 CF3 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl
232 CF3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
233 CF3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1
234 CF3 2 , 6-diF-phenyl 2- (methylsulfonyl) henyl
235 CF3 2, 6-diF-phenyl 4-morpho1ino
236 CF3 2, 6-diF-phenyl 2- (l'-CF3-tetrazol-2-yl)phenyl
237 CF3 2 , 6-diF-phenyl 4-morpho1inocarbony1
238 CF3 2 , 6-diF-phenyl 2-methyl-1-imidazolyl
239 CF3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 240 CF3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
241 SCH3 phenyl 2- (aminosulfony1 ) phenyl 242 SCH3 phenyl 2- (methylaminosulfonyl) phenyl 243 SCH3 phenyl 1-pyrrolidinocarbonyl 244 SCH3 phenyl 2- (methylsulfonyl ) phenyl 245 SCH3 phenyl 4-morpholino 246 SCH3 phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 247 SCH3 phenyl 4-morpholinocarbonyl 248 SCH3 phenyl 2-methyl-l-imidazolyl 249 SCH3 phenyl 5-methyl-l-imidazolyl 250 SCH3 phenyl 2-methylsulfonyl-l-imidazolyl
251 SCH3 2-pyridyl 2- (aminosulfonyl ) phenyl
252 SCH3 2-pyridyl 2- (methylaminosulfonyl ) phenyl
253 SCH3 2-pyridyl 1-pyrro1idinocarbony1
254 SCH3 2-pyridyl 2- (methylsulfonyl ) phenyl
255 SCH3 2-pyridyl 4-morpholino
256 SCH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
257 SCH3 2-pyridyl 4-morpholinocarbonyl
258 SCH3 2-pyridyl 2-methyl-l-imidazolyl
259 SCH3 2-pyridyl 5-methyl-l-imidazolyl
260 SCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
261 SCH3 3-pyridyl 2- (aminosulfonyl) phenyl
262 SCH3 3-pyridyl 2- (methylaminosulfonyl ) phenyl
263 SCH3 3-pyridyl 1-pyrrolidinocarbonyl
264 SCH3 3-pyridyl 2- (methylsulfonyl) phenyl
265 SCH3 3-pyridyl 4-morpholino
266 SCH3 3-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl
267 SCH3 3-pyridyl 4-morpho1inocarbony1
268 SCH3 3-pyridyl 2-methyl-l-imidazolyl
269 SCH3 3-pyridyl 5-methyl-l-imidazolyl
270 SCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
271 SCH3 2-pyrimidyl 2- (aminosulfonyl ) phenyl
272 SCH3 2-pyrimidyl 2- (methylaminosulfonyl ) phenyl
273 SCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
274 SCH3 2-pyrimidyl 2- (methylsulfonyl ) phenyl
275 SCH3 2-pyrimidyl 4-morpholino
276 SCH3 2-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl 277 SCH3 2-pyrimidyl 4-morpholinocarbonyl
278 SCH3 2-pyrimidyl 2-methyl-l-imidazolyl
279 SCH3 2-pyrimidyl 5-methyl-l-imidazolyl
280 SCH 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
281 SCH3 5-pyrimidyl 2- (aminosulfonyl) phenyl
282 SCH3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
283 SCH3 5-pyrimidyl 1-pyrrolidinocarbonyl
284 SCH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
285 SCH3 5-pyrimidyl 4-morpho1ino
286 SCH3 5-pyrimidyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl
287 SCH 5-pyrimidyl 4-morpholinocarbonyl
288 SCH3 5-pyrimidyl 2-methyl-l-imidazolyl
289 SCH3 5-pyrimidyl 5-methyl-l-imidazolyl
290 SCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
291 SCH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl
292 SCH3 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl
293 SCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
294 SCH3 2-Cl-phenyl 2- (methylsulfonyl)phenyl
295 SCH3 2-Cl-phenyl 4-morpho1ino
296 SCH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl
297 SCH3 2-Cl-phenyl 4-morpho1inocarbony1
298 SCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
299 SCH3 2-Cl-phenyl 5-methyl-l-imidazolyl
300 SCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
301 SCH3 2-F-phenyl 2- (aminosulfonyl)phenyl
302 SCH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl
303 SCH3 2-F-phenyl 1-pyrro1idinocarbony1
304 SCH3 2-F-phenyl 2- (methylsulfonyl) phenyl
305 SCH3 2-F-phenyl 4-morpholino
306 SCH3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
307 SCH3 2-F-phenyl 4-morpholinocarbonyl
308 SCH3 2-F-phenyl 2-methyl-l-imidazolyl
309 SCH3 2-F-phenyl 5-methyl-l-imidazolyl
310 SCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
311 SCH3 2 , 6-diF-phenyl 2- (aminosulfonyl)phenyl
312 SCH3 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
313 SCH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 314 SCH3 2 , 6-diF-phenyl 2- (methylsulfonyl ) phenyl
315 SCH3 2 , 6-diF-phenyl 4-morpholino
316 SCH3 2, 6-diF-phenyl 2- ( l ' -CF3 - tetrazol-2 -yD phenyl
317 SCH3 2, 6-diF-phenyl 4-morpholinocarbonyl
318 SCH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
319 SCH3 2 , 6-diF-phenyl 5-methy1-1-imidazolyl
320 SCH 2 , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
321 SOCH3 phenyl 2- (aminosulfonyl) phenyl
322 SOCH3 phenyl 2- (methylaminosulfonyl) phenyl
323 SOCH3 phenyl 1-pyrrolidinocarbonyl
324 SOCH3 phenyl 2- (methylsulfonyl) phenyl
325 SOCH3 phenyl 4-morpholino
326 SOCH3 phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl
327 SOCH3 phenyl 4-morpholinocarbonyl
328 SOCH3 phenyl 2-methyl-l-imidazolyl
329 SOCH3 phenyl 5-methyl-l-imidazolyl
330 SOCH3 phenyl 2-methylsulfonyl-l-imidazolyl
331 SOCH3 2-pyridyl 2- (aminosulfonyl ) phenyl
332 SOCH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
333 SOCH3 2-pyridyl 1-pyrrolidinocarbonyl
334 SOCH3 2-pyridyl 2- (methylsulfonyl) phenyl
335 SOCH3 2-pyridyl 4-morpholino
336 SOCH3 2-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
337 SOCH3 2-pyridyl 4-morpholinocarbonyl
338 SOCH3 2-pyridyl 2-methyl-l-imidazolyl
339 SOCH3 2-pyridyl 5-methyl-l-imidazolyl
340 SOCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
341 SOCH3 3-pyridyl 2- (aminosulfonyl) phenyl
342 SOCH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
343 SOCH3 3-pyridyl 1-pyrrolidinocarbonyl
344 SOCH3 3-pyridyl 2- (methylsulfonyl)phenyl
345 SOCH3 3-pyridyl 4-morpholino
346 SOCH3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
347 SOCH3 3-pyridyl 4-morpholinocarbonyl
348 SOCH3 3-pyridyl 2-methyl-l-imidazolyl
349 SOCH3 3-pyridyl 5-methyl-l-imidazolyl
350 SOCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl 351 SOCH3 2-pyrimidyl 2- (aminosulfonyl)phenyl
352 SOCH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
353 SOCH3 2-pyrimidyl 1-pyrrolidinocarbonyl
354 SOCH3 2-pyrimidyl 2- (methylsulfonyl)phenyl
355 SOCH3 2-pyrimidyl 4-morpholino
356 SOCH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
357 SOCH3 2-pyrimidyl 4-morpholinocarbonyl
358 SOCH3 2-pyrimidyl 2-methyl-l-imidazolyl
359 SOCH3 2-pyrimidyl 5-methyl-l-imidazolyl
360 SOCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
361 SOCH3 5-pyrimidyl 2- (aminosulfonyl)phenyl
362 SOCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
363 SOCH3 5-pyrimidyl 1-pyrrolidinocarbony1
364 SOCH3 5-pyrimidyl 2- (methylsulfonyl)phenyl
365 SOCH3 5-pyrimidyl 4-morpholino
366 SOCH3 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl)phenyl
367 SOCH3 5-pyrimidyl 4-morpholinocarbonyl
368 SOCH3 5-pyrimidyl 2-methyl-l-imidazolyl
369 SOCH3 5-pyrimidyl 5-methyl-l-imidazolyl
370 SOCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
371 SOCH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl
372 SOCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
373 SOCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl
374 SOCH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl
375 SOCH3 2-Cl-phenyl 4-morpho1ino
376 SOCH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-y phenyl
377 SOCH3 2-Cl-phenyl 4-morpho1inocarbony1
378 SOCH3 2-Cl-phenyl 2-methyl-l-imidazolyl
379 SOCH3 2-Cl-phenyl 5-methyl-l-imidazolyl
380 SOCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
381 SOCH3 2-F-phenyl 2- (aminosulfonyl) henyl 382 SOCH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 383 SOCH3 2-F-phenyl 1-pyrrolidinocarbonyl 384 SOCH3 2-F-phenyl 2- (methylsulfonyl) phenyl 385 SOCH3 2-F-phenyl 4-morpho1ino 386 SOCH3 2-F-phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 387 SOCH3 2-F-phenyl 4-morpho1inocarbony1 388 SOCH3 2-F-phenyl 2-methyl-l-imidazolyl 389 SOCH3 2-F-phenyl 5-methyl-l-imidazolyl 390 SOCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
391 SOCH3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
392 SOCH3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
393 SOCH3 2 , 6-diF-phenyl 1-pyrro1idinocarbony1
394 SOCH3 2, 6-diF-phenyl 2- (methylsulfonyl)phenyl
395 SOCH3 2, 6-diF-phenyl 4-morpholino
396 SOCH3 2, 6-diF-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl
397 SOCH3 2, 6-diF-phenyl 4-morpholinocarbonyl
398 SOCH3 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
399 SOCH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
400 SOCH3 2, 6-diF-phenyl 2-methylsulfonyl-1-imidazolyl
401 SO2CH3 phenyl 2- (aminosulfonyl) phenyl
402 S02CH3 phenyl 2- (methylaminosulfonyl)phenyl
403 S02CH3 phenyl 1-pyrro1idinocarbony1
404 S02CH3 phenyl 2- (methylsulfonyl) henyl
405 SO2CH3 phenyl 4-morpholino
406 SO2CH3 phenyl 2-(l' -CF3-tetrazol-2-yDphenyl
407 S02CH3 phenyl 4-morpholinocarbonyl
408 S0 CH3 phenyl 2-methyl-l-imidazolyl
409 S02CH3 phenyl 5-methyl-1-imidazolyl
410 S02CH3 phenyl 2-methylsulfonyl-l-imidazolyl
411 S0 CH3 2-pyridyl 2- (aminosulfonyl) phenyl
412 SO2CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
413 SO2CH3 2-pyridyl 1-py ro1idinocarbony1
414 SO2CH3 2-pyridyl 2- (methylsulfonyl) phenyl
415 S02CH3 2-pyridyl 4-morpholino
416 S02CH3 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl
417 S02CH3 2-pyridyl 4-morpholinocarbonyl
418 S02CH3 2-pyridyl 2-methyl-l-imidazolyl
419 SO2CH3 2-pyridyl 5-methyl-l-imidazolyl
420 S02CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
421 SO2CH3 3-pyridyl 2- (aminosulfonyl)phenyl
422 SO2CH3 3-pyridyl 2- (methylaminosulfonyl)phenyl
423 SO2CH3 3-pyridyl 1-pyrro1idinocarbony1
424 SO2CH3 3 -pyridyl 2- (methylsulfonyl) phenyl 425 S02CH3 3-pyridyl 4-morpholino
426 S02CH3 3-pyridyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl
427 SO2CH3 3-pyridyl 4-morpholinocarbonyl
428 SO2CH3 3-pyridyl 2-methyl-l-imidazolyl
429 SO2CH3 3-pyridyl 5-methyl-l-imidazolyl
430 S02CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
431 S02CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 432 S02CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 433 SO2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 434 S02CH3 2-pyrimidyl 2- (methylsulfonyl) phenyl 435 S02CH3 2-pyrimidyl 4-morpholino 436 S02CH3 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl 437 S02CH3 2-pyrimidyl 4-morpho1inocarbony1 438 S02CH3 2-pyrimidyl 2-methyl-l-imidazolyl 439 S0CH3 2-pyrimidyl 5-methyl-l-imidazolyl 440 SQ2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
441 S02CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl 442 S0CH3 5-pyrimidyl 2- (methylaminosulfonyl)phenyl 443 S02CH3 5-pyrimidyl 1-pyrro1idinocarbony1 444 S02CH3 5-pyrimidyl 2- (methylsulfonyl ) phenyl 445 S02CH3 5-pyrimidyl 4-morpho1ino 446 S02CH3 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 447 SO2CH3 5-pyrimidyl 4-morpholinocarbonyl 448 S02CH3 5-pyrimidyl 2-methyl-1-imidazoly1 449 S02CH3 5-pyrimidyl 5-methyl-l-imidazolyl 450 S02CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
451 S02CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 452 S02CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 453 SO2CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 454 S02CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 455 S02CH3 2-Cl-phenyl 4-morpholino 456 S02CH3 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl 457 SO2CH3 2-Cl-phenyl 4-morpholinocarbonyl 458 SO2CH3 2-Cl-phenyl 2-methy1-1-imidazolyl 459 SO2CH3 2-Cl-phenyl 5-methyl-l-imidazolyl 460 SQ2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
461 SO2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl 462 S02CH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 463 S02CH3 2-F-phenyl 1-pyrro1idinocarbony1 464 S02CH3 2-F-phenyl 2- (methylsulfonyl)phenyl 465 S02CH3 2-F-phenyl 4-morpholino 466 SO2CH3 2-F-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl 467 SO2CH3 2-F-phenyl 4-morpholinocarbonyl 468 SO2CH3 2-F-phenyl 2-methyl-l-imidazolyl 469 SO2CH3 2-F-phenyl 5-methyl-l-imidazolyl 470 SO2CH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
471 S02CH3 2,6-diF-phenyl 2- (aminosulfonyl)phenyl
472 S02CH3 2,6-diF-phenyl 2- (methylaminosulfonyl)phenyl
473 S02CH3 2,6-diF-phenyl 1-pyrrolidinocarbonyl
474 SO2CH3 2,6-diF-phenyl 2- (methylsulfonyl) phenyl
475 SO2CH3 2,6-diF-phenyl 4-morpholino
476 SO2CH3 2,6-diF-phenyl 2- ( 1 ' -CF3 - tetrazol-2 -yD phenyl
477 SO2CH3 2,6-diF-phenyl 4-morpholinocarbonyl
478 SO2CH3 2,6-diF-phenyl 2-methyl-l-imidazolyl
479 SO2CH3 2,6-diF-phenyl 5-methyl-l-imidazolyl
480 SO2CH3 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
481 CHNH- phenyl 2- (aminosulfonyl) phenyl SO2CH3
482 CH2NH- phenyl 2- (methylaminosulfonyl) phenyl SO2CH3
483 CH2NH- phenyl 1-pyrrolidinocarbonyl SO2CH3
484 CH2NH- phenyl 2- (methylsulfonyl)phenyl S0CH3
485 CH2NH- phenyl 4-morpho1ino SO2CH3
486 CH2NH- phenyl 2-(l' -CF3-tetrazol-2-yDphenyl SO2CH3
487 CH2NH- phenyl 4-morpholinocarbonyl S02CH3
488 CH2NH- phenyl 2-methyl-l-imidazolyl SO2CH3
489 CH2NH- phenyl 5-methyl-l-imidazolyl SO2CH3 490 CH2NH- phenyl 2-methylsulfonyl-l-imidazolyl S02CH3
491 CH2NH- 2-pyridyl 2- (aminosulfonyl) phenyl SO2CH3
492 CH2NH- 2-pyridyl 2- (methylaminosulfonyl)phenyl SO2CH3
493 CH2NH- 2-pyridyl 1-pyrrolidinocarbonyl S02CH3
494 CH2NH- 2-pyridyl 2- (methylsulfonyl) phenyl SO2CH3
495 CH2NH- 2-pyridyl 4-morpholino SO2CH3
496 CH2NH- 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl SO2CH3
497 CH2NH- 2-pyridyl 4-morpholinocarbonyl S02CH3
498 CH2NH- 2-pyridyl 2-methyl-l-imidazolyl S02CH3
499 CH2NH- 2-pyridyl 5-methyl-l-imidazolyl S02CH3
500 CH2NH- 2-pyridyl 2-methylsulfonyl-l-imidazolyl S02CH3
501 CH2NH- 3-pyridyl 2- (aminosulfonyl) phenyl SO2CH3
502 CH2NH- 3-pyridyl 2- (methylaminosulfonyl) phenyl SO2CH3
503 CH2NH- 3-pyridyl 1-pyrrolidinocarbonyl SO2CH3
504 CH2NH- 3-pyridyl 2- (methylsulfonyl) phenyl SO2CH3
505 CH2NH- 3-pyridyl 4-morpho1ino SO2CH3
506 CH2NH- 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl SO2CH3
507 CH2NH- 3-pyridyl 4-morpholinocarbonyl SO2CH3 508 CH2NH- 3-pyridyl 2-methyl-l-imidazolyl S0CH3
509 CH2NH- 3-pyridyl 5-methyl-l-imidazolyl SO2CH3
510 CH2NH- 3-pyridyl 2-methylsulfonyl-l-imidazolyl SO2CH3
511 CHNH- 2-pyrimidyl 2- (aminosulfonyl)phenyl SO2CH3
512 CH2NH- 2-pyrimidyl 2- (methylaminosulfonyl) phenyl SO2CH3
513 CH2NH- 2-pyrimidyl 1-pyrrolidinocarbonyl S0CH3
514 CH2NH- 2-pyrimidyl 2- (methylsulfonyl) phenyl SO2CH3
515 CHNH- 2-pyrimidyl 4-morpholino S02CH3
516 CH2NH- 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl SO2CH3
517 CHNH- 2-pyrimidyl 4-morpholinocarbonyl SO2CH3
518 CH2NH- 2-pyrimidyl 2-methyl-l-imidazolyl SO2CH3
519 CH2NH- 2-pyrimidyl 5-methyl-l-imidazolyl SO2CH3
520 CH2NH- 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl SO2CH3
521 CH2NH- 5-pyrimidyl 2- (aminosulfonyl)phenyl SO2CH3
522 CH2NH- 5-pyrimidyl 2- (methylaminosulfonyl)phenyl S02CH3
523 CH2NH- 5-pyrimidyl 1-pyrrolidinocarbonyl S02CH3
524 CH2NH- 5-pyrimidyl 2- (methylsulfonyl)phenyl SO2CH3
525 CH2NH- 5-pyrimidyl 4-morpho1ino S0CH3 526 CH2NH- 5-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl S02CH3 527 CH2NH- 5-pyrimidyl 4-morpholinocarbonyl SO2CH3 528 CH2NH- 5-pyrimidyl 2-methyl-l-imidazolyl SO2CH3 529 CH2NH- 5-pyrimidyl 5-methyl-l-imidazolyl SO2CH3
530 CH2NH- 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl SQ2CH3
531 CH2NH- 2-Cl-phenyl 2- (aminosulfonyl)phenyl S02CH3
532 CH2NH- 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl S02CH3
533 CH2NH- 2-Cl-phenyl 1-pyrrolidinocarbonyl S0CH3
534 CH2NH- 2-Cl-phenyl 2- (methylsulfonyl) phenyl S02CH3
535 CH2NH- 2-Cl-phenyl 4-morpholino SO2CH3
536 CH2NH- 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yDphenyl SO2CH3
537 CH2NH- 2-Cl-phenyl 4-morpholinocarbonyl S02CH3
538 CH2NH- 2-Cl-phenyl 2-methyl-l-imidazolyl S02CH3
539 CH2NH- 2-Cl-phenyl 5-methyl-l-imidazolyl SO2CH3
540 CH2NH- 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl SO2CH3
541 CH2NH- 2-F-phenyl 2- (aminosulfonyl) phenyl SO2CH3
542 CH2NH- 2-F-phenyl 2- (methylaminosulfonyl)phenyl S02CH3
543 CH2NH- 2-F-phenyl 1-pyrrolidinocarbonyl S02CH3 544 CH2NH- 2-F-phenyl 2- (methylsulfonyl ) phenyl S02CH3
545 CH2NH- 2-F-phenyl 4-morpholino S02CH3
546 CH2NH- 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl SO2CH3
547 CH2NH- 2-F-phenyl 4-morpholinocarbonyl S02CH3
548 CH2NH- 2-F-phenyl 2-methyl-l-imidazolyl S02CH3
549 CH2NH- 2-F-phenyl 5-methyl-l-imidazolyl S02CH3
550 CHNH- 2-F-phenyl 2-methylsulfonyl-l-imidazolyl S0CH
551 CHNH- 2 , 6-diF-phenyl 2- (aminosulfonyl) phenyl S0CH3
552 CH2NH- 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl SO2CH3
553 CH2NH- 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl SO2CH3
554 CH2NH- 2, , 6-diF-phenyl 2- (methylsulfonyl) phenyl S02CH3
555 CH2NH- 2, , 6-diF-phenyl 4-morpholino SO2CH3
556 CH2NH- 2, , 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl SO2CH3
557 CH2NH- 2, , 6-diF-phenyl 4-morpholinocarbonyl S02CH3
558 CH2NH- 2 , , 6-diF-phenyl 2-methyl-l-imidazolyl S02CH3
559 CHNH- 2, .6-diF-phenyl 5-methyl-l-imidazolyl S02CH3
560 CH2NH- 2, , 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl S0CH3
561 Cl phenyl 2- (aminosulfonyl) phenyl
562 Cl phenyl 2- (methylaminosulfonyl)phenyl
563 Cl phenyl 1-pyrr01idinocarbony1 564 Cl phenyl 2- (methylsulfonyl)phenyl 565 Cl phenyl 4-morpho1ino 566 Cl phenyl 2- (1' -CF3-tetrazol-2-yl) phenyl 567 Cl phenyl 4-morpholinocarbonyl 568 Cl phenyl 2-methyl-l-imidazolyl 569 Cl phenyl 5-methyl-l-imidazolyl 570 Cl phenyl 2-methylsulfonyl-l-imidazolyl
571 Cl 2-pyridyl 2- (aminosulfonyl) phenyl
572 Cl 2-pyridyl 2- (methylaminosulfonyl)phenyl
573 Cl 2-pyridyl 1-pyrrolidinocarbonyl
574 Cl 2-pyridyl 2- (methylsulfonyl) henyl
575 Cl 2-pyridyl 4-morpholino
576 Cl 2-pyridyl 2- (1 ' -CF3 -tetrazol-2-yl)phenyl
577 Cl 2-pyridyl 4-morpholinocarbonyl
578 Cl 2-pyridyl 2-methyl-l-imidazolyl
579 Cl 2-pyridyl 5-methyl-l-imidazolyl
580 Cl 2-pyridyl 2-methylsulfonyl-l-imidazolyl
581 Cl 3-pyridyl 2- (aminosulfonyl) phenyl
582 Cl 3-pyridyl 2- (methylaminosulfonyl)phenyl
583 Cl 3-pyridyl 1-pyrro1idinocarbony1
584 Cl 3-pyridyl 2- (methylsulfonyl) phenyl
585 Cl 3-pyridyl 4-morpho1ino
586 Cl 3-pyridyl 2- (1' -CF3-tetrazol-2-yDphenyl
587 Cl 3-pyridyl 4-morpholinocarbonyl
588 Cl 3-pyridyl 2-methyl-l-imidazolyl
589 Cl 3-pyridyl 5-methyl-l-imidazolyl
590 Cl 3-pyridyl 2-methylsulfonyl-l-imidazolyl
591 Cl 2-pyrimidyl 2- (aminosulfonyl)phenyl
592 Cl 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
593 Cl 2-pyrimidyl 1-pyrrolidinocarbonyl
594 Cl 2-pyrimidyl 2- (methylsulfonyl)phenyl
595 Cl 2-pyrimidyl 4-morpho1ino
596 Cl 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
597 Cl 2-pyrimidyl 4-morpholinocarbonyl
598 Cl 2-pyrimidyl 2-methyl-l-imidazolyl
599 Cl 2-pyrimidyl 5-methyl-l-imidazolyl
600 Cl 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl 601 Cl 5-pyrimidyl 2- (aminosulfonyl) phenyl
602 Cl 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
603 Cl 5-pyrimidyl 1-pyrro1idinocarbony1
604 Cl 5-pyrimidyl 2- (methylsulfonyl) phenyl
605 Cl 5-pyrimidyl 4-morpholino
606 Cl 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yDphenyl
607 Cl 5-pyrimidyl 4-morpholinocarbonyl
608 Cl 5-pyrimidyl 2-methyl-l-imidazolyl
609 Cl 5-pyrimidyl 5-methyl-l-imidazolyl
610 Cl 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
611 Cl 2-Cl-phenyl 2- (aminosulfonyl) phenyl
612 Cl 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
613 Cl 2-Cl-phenyl 1-pyrrolidinocarbonyl
614 Cl 2-Cl-phenyl 2- (methylsulfonyl) phenyl
615 Cl 2-Cl-phenyl 4-morpholino
616 Cl 2-Cl-phenyl 2- (1 '-CF3-tetrazol-2-yD henyl
617 Cl 2-Cl-phenyl 4-morpholinocarbonyl
618 Cl 2-Cl-phenyl 2-methyl-l-imidazolyl
619 Cl 2-Cl-phenyl 5-methyl-l-imidazolyl
620 Cl 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
621 Cl 2-F-phenyl 2- (aminosulfonyl) phenyl
622 Cl 2-F-phenyl 2- (methylaminosulfonyl)phenyl
623 Cl 2-F-phenyl 1-pyrrolidinocarbonyl
624 Cl 2-F-phenyl 2- (methylsulfonyl) phenyl
625 Cl 2-F-phenyl 4-morpholino
626 Cl 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
627 Cl 2-F-phenyl 4-morpho1inocarbony1
628 Cl 2-F-phenyl 2-methyl-l-imidazolyl
629 Cl 2-F-phenyl 5-methyl-l-imidazolyl
630 Cl 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
631 Cl 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl
632 Cl 2, 6-diF-phenyl 2- (methylaminosulfonyl)phenyl
633 Cl 2,6-diF-phenyl 1-pyrrolidinocarbonyl
634 Cl 2, 6-diF-phenyl 2- (methylsulfonyl) phenyl
635 Cl 2,6-diF-phenyl 4-morpho1ino
636 Cl 2, 6-diF-phenyl 2- ( 1 ' -CF3 -tetrazol -2 -yD phenyl
637 Cl 2, 6-diF-phenyl 4-morpholinocarbonyl 638 Cl 2,6-diF-phenyl 2-methyl-l-imidazolyl
639 Cl 2,6-diF-phenyl 5-methyl-l-imidazolyl
640 Cl 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
641 F phenyl 2- (aminosulfonyl) phenyl 642 F phenyl 2- (methylaminosulfonyl) phenyl 643 F phenyl 1-pyrrolidinocarbonyl 644 F phenyl 2- (methylsulfonyl) phenyl 645 F phenyl 4-morpho1ino 646 F phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl 647 F phenyl 4-morpholinocarbonyl 648 F phenyl 2-methyl-l-imidazolyl 649 F phenyl 5-methyl-l-imidazolyl 650 F phenyl 2-methylsulfonyl-l-imidazolyl
651 F 2-pyridyl 2- (aminosulfonyl) phenyl 652 F 2-pyridyl 2- (methylaminosulfonyl) phenyl 653 F 2-pyridyl 1-pyrrolidinocarbonyl 654 F 2-pyridyl 2- (methylsulfonyl) phenyl 655 F 2-pyridyl 4-morpho1ino 656 F 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 657 F 2-pyridyl 4-morpholinocarbonyl 658 F 2-pyridyl 2-methyl-l-imidazolyl 659 F 2-pyridyl 5-methyl-l-imidazolyl 660 F 2-pyridyl 2-methylsulfonyl-l-imidazolyl
661 F 3-pyridyl 2- (aminosulfonyl)phenyl 662 F 3-pyridyl 2- (methylaminosulfonyl)phenyl 663 F 3-pyridyl 1-pyrrolidinocarbonyl 664 F 3-pyridyl 2- (methylsulfonyl)phenyl 665 F 3-pyridyl 4-morpholino 666 F 3-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl 667 F 3-pyridyl 4-morpholinocarbonyl 668 F 3-pyridyl 2-methyl-l-imidazolyl 669 F 3-pyridyl 5-methyl-l-imidazolyl 670 F 3-pyridyl 2-methylsulfonyl-l-imidazolyl
671 F 2-pyrimidyl 2- (aminosulfonyl)phenyl
672 F 2-pyrimidyl 2- (methylaminosulfonyl)phenyl
673 F 2-pyrimidyl 1-pyrro1idinocarbony1
674 F 2-pyrimidyl 2- (methylsulfonyl)phenyl 675 F 2-pyrimidyl 4-morpholino
676 F 2-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl
677 F 2-pyrimidyl 4-morpho1inocarbony1
678 F 2-pyrimidyl 2-methyl-1-imidazolyl
679 F 2-pyrimidyl 5-methyl-l-imidazolyl
680 F 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
681 F 5-pyrimidyl 2- (aminosulfonyl) phenyl
682 F 5-pyrimidyl 2- (methylaminosulfonyl) phenyl
683 F 5-pyrimidyl 1-pyrrolidinocarbonyl
684 F 5-pyrimidyl 2- (methylsulfonyl) phenyl
685 F 5-pyrimidyl 4-morpholino
686 F 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl
687 F 5-pyrimidyl 4-morpholinocarbonyl
688 F 5-pyrimidyl 2-methyl-l-imidazolyl
689 F 5-pyrimidyl 5-methyl-l-imidazolyl
690 F 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
691 F 2-Cl-phenyl 2- (aminosulfonyl) phenyl
692 F 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl
693 F 2-Cl-phenyl 1-pyrrolidinocarbonyl
694 F 2-Cl-phenyl 2- (methylsulfonyl) phenyl
695 F 2-Cl-phenyl 4-morpholino
696 F 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yl) henyl
697 F 2-Cl-phenyl 4-morpho1inocarbony1
698 F 2-Cl-phenyl 2-methyl-l-imidazolyl
699 F 2-Cl-phenyl 5-methyl-l-imidazolyl
700 F 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
701 F 2-F-phenyl 2- (aminosulfonyl) phenyl
702 F 2-F-phenyl 2- (methylaminosulfonyl)phenyl
703 F 2-F-phenyl 1-pyrro1idinocarbony1
704 F 2-F-phenyl 2- (methylsulfonyl) phenyl
705 F 2-F-phenyl 4-morpho1ino
706 F 2-F-phenyl 2- ( D -CF3 -tetrazol-2 -yD phenyl
707 F 2-F-phenyl 4-morpholinocarbonyl
708 F 2-F-phenyl 2-methyl-l-imidazolyl
709 F 2-F-phenyl 5-methy1-1-imidazoly1
710 F 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
711 2, 6-diF-phenyl 2- (aminosulfonyl)phenyl 712 F 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
713 F 2, 6-diF-phenyl 1-pyrrolidinocarbonyl
714 F 2 , 6-diF-phenyl 2- (methylsulfonyl) phenyl
715 F 2, 6-diF-phenyl 4-morpholino
716 F 2, 6-diF-phenyl 2- ( 1 ' -CF3-tetrazol-2-yl) phenyl
717 F 2, 6-diF-phenyl 4-morpholinocarbonyl
718 F 2 , 6-diF-phenyl 2-methyl-l-imidazolyl
719 F 2, 6-diF-phenyl 5-methyl-l-imidazolyl
720 F 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
721 C02CH3 phenyl 2- (aminosulfonyl) phenyl
722 CO2CH3 phenyl 2- (methylaminosulfonyl) phenyl
723 CO2CH3 phenyl 1-pyrrolidinocarbonyl
724 C02CH3 phenyl 2- (methylsulfonyl)phenyl
725 C02CH3 phenyl 4-morpholino
726 C02CH3 phenyl 2- (1' -CF3-tetrazol-2-yl)phenyl
727 C02CH3 phenyl 4-morpholinocarbonyl
728 C02CH3 phenyl 2-methyl-l-imidazolyl
729 C02CH3 phenyl 5-methyl-l-imidazolyl
730 C02CH phenyl 2-methylsulfonyl-l-imidazolyl
731 C02CH3 2-pyridyl 2- (aminosulfonyl) phenyl
732 C02CH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
733 CO2CH3 2-pyridyl 1-pyrro1idinocarbony1
734 CO2CH3 2-pyridyl 2- (methylsulfonyl) phenyl
735 C02CH3 2-pyridyl 4-morpho1ino
736 C0 CH3 2-pyridyl 2- (l'-CF3-tetrazol-2-yDphenyl
737 C02CH3 2-pyridyl 4-morpholinocarbonyl
738 C02CH3 2-pyridyl 2-methyl-l-imidazolyl
739 C02CH3 2-pyridyl 5-methyl-l-imidazolyl
740 C02CH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
741 C02CH 3-pyridyl 2- (aminosulfonyl) phenyl
742 CO2CH3 3-pyridyl 2- (methylaminosulfonyl) phenyl
743 CO2CH3 3-pyridyl 1-pyrro1idinocarbony1
744 CO2CH3 3 -pyridyl 2- (methylsulfonyl) phenyl
745 CO2CH3 3 -pyridyl 4-morpholino
746 C02CH3 3-pyridyl 2- ( 1 ' -CF3 -tetrazol-2 -yD phenyl
747 C02CH3 3-pyridyl 4-morpholinocarbonyl
748 C0CH3 3-pyridyl 2-methyl-l-imidazolyl 749 C0CH3 3-pyridyl 5-methyl-l-imidazolyl
750 CO2CH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
751 C02CH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 752 C02CH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 753 CO2CH3 2-pyrimidyl 1-pyrrolidinocarbonyl 754 CO2CH3 2-pyrimidyl 2- (methylsulfonyl)phenyl 755 CO2CH3 2-pyrimidyl 4-morpholino 756 CO2CH3 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 757 CO2CH3 2-pyrimidyl 4-morpholinocarbonyl 758 CO2CH3 2-pyrimidyl 2-methyl-l-imidazolyl 759 C02CH3 2-pyrimidyl 5-methyl-l-imidazolyl 760 CO2CH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
761 C02CH3 5-pyrimidyl 2- (aminosulfonyl) phenyl 762 CO2CH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 763 CO2CH3 5-pyrimidyl 1-pyrrolidinocarbonyl 764 CO2CH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 765 C0 CH3 5-pyrimidyl 4-morpho1ino 766 C02CH3 5-pyrimidyl 2- (l'-CF3-tetrazol-2-yl) phenyl 767 CO2CH3 5-pyrimidyl 4-morpholinocarbonyl 768 CO2CH3 5-pyrimidyl 2-methyl-l-imidazolyl 769 CO2CH3 5-pyrimidyl 5-methyl-l-imidazolyl 770 CO2CH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
771 CO2CH3 2-Cl-phenyl 2- (aminosulfonyl) phenyl 772 C02CH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 773 C02CH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 774 CO2CH3 2-Cl-phenyl 2- (methylsulfonyl) phenyl 775 CO2CH3 2-Cl-phenyl 4-morpholino 776 CO2CH3 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yDphenyl 777 CO2CH3 2-Cl-phenyl 4-morpholinocarbonyl 778 CO2CH3 2-Cl-phenyl 2-methyl-l-imidazolyl 779 C02CH3 2-Cl-phenyl 5-methyl-l-imidazolyl 780 CQ2CH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
781 CO2CH3 2-F-phenyl 2- (aminosulfonyl) phenyl 782 CO2CH3 2-F-phenyl 2- (methylaminosulfonyl)phenyl 783 C02CH3 2-F-phenyl 1-pyrro1idinocarbony1 784 CO2CH3 2-F-phenyl 2- (methylsulfonyl)phenyl 785 CO2CH3 2-F-phenyl 4-morpholino 786 C02CH3 2 -F-phenyl 2 - ( l ' -CF3 - tetrazol-2 -yD phenyl 787 C02CH3 2 -F-phenyl 4-morpholinocarbonyl 788 CO2CH3 2 -F-phenyl 2-methyl-l-imidazolyl 789 CO2CH3 2 -F-phenyl 5-methyl-l-imidazolyl 790 CO2CH3 2 -F-phenyl 2-methylsulfonyl-l-imidazolyl
791 CO2CH3 2, , 6-diF-phenyl 2- (aminosulfonyl) phenyl
792 CO2CH3 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
793 CO2CH3 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl
794 CO2CH3 2, .6-diF-phenyl 2- (methylsulfonyl)phenyl
795 CO2CH3 2, .6-diF-phenyl 4-morpholino
796 CO2CH3 2, .6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
797 C0CH3 2, .6-diF-phenyl 4-morpholinocarbonyl
798 C02CH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl
799 C02CH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl
800 C02CH 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
801 CH2OCH3 phenyl 2- (aminosulfonyl) phenyl
802 CH2OCH3 phenyl 2- (methylaminosulfonyl) phenyl
803 CH2OCH3 phenyl 1-pyrrolidinocarbonyl
804 CH2OCH3 phenyl 2- (methylsulfonyl) phenyl
805 CH2OCH3 phenyl 4-morpholino
806 CH2OCH3 phenyl 2- (1' -CF3-tetrazol-2-yDphenyl
807 CH2OCH3 phenyl 4-morpho1inocarbony1
808 CH2OCH3 phenyl 2-methyl-l-imidazolyl
809 CH2OCH3 phenyl 5-methyl-l-imidazolyl
810 CH2OCH3 phenyl 2-methylsulfonyl-l-imidazolyl
811 CH2OCH3 2-pyridyl 2- (aminosulfonyl) phenyl
812 CH2OCH3 2-pyridyl 2- (methylaminosulfonyl) phenyl
813 CH2OCH3 2-pyridyl 1-pyrrolidinocarbonyl
814 CH2OCH3 2-pyridyl 2- (methylsulfonyl) phenyl
815 CH2OCH3 2-pyridyl 4-morpho1ino
816 CH2OCH3 2-pyridyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl
817 CH2OCH3 2-pyridyl 4-morpho1inocarbony1
818 CH2OCH3 2-pyridyl 2-methyl-l-imidazolyl
819 CH2OCH3 2-pyridyl 5-methyl-l-imidazolyl
820 CH2OCH3 2-pyridyl 2-methylsulfonyl-l-imidazolyl
821 CH2OCH3 3-pyridyl 2- (aminosulfonyl)phenyl
822 CH2OCH3 3-pyridyl 2- (methylaminosulfonyl) phenyl 823 CH2OCH3 3-pyridyl 1-pyrrolidinocarbonyl
824 CH2OCH3 3-pyridyl 2- (methylsulfonyl) phenyl
825 CH2OCH3 3-pyridyl 4-morpholino
826 CH2OCH3 3-pyridyl 2- (1' -CF3-tetrazol-2-yl) phenyl
827 CH2OCH3 3-pyridyl 4-morpholinocarbonyl
828 CH2OCH3 3-pyridyl 2-methyl-l-imidazolyl
829 CH2OCH3 3-pyridyl 5-methyl-l-imidazolyl
830 CH2OCH3 3-pyridyl 2-methylsulfonyl-l-imidazolyl
831 CH2OCH3 2-pyrimidyl 2- (aminosulfonyl) phenyl 832 CH2OCH3 2-pyrimidyl 2- (methylaminosulfonyl) phenyl 833 CH2OCH3 2-pyrimidyl 1-pyrrolidinocarbonyl 834 CH2OCH3 2-pyrimidyl 2- (methylsulfonyl) phenyl 835 CH2OCH3 2-pyrimidyl 4-morpho1ino 836 CH2OCH3 2-pyrimidyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 837 CH2OCH3 2-pyrimidyl 4-morpholinocarbonyl 838 CH2OCH3 2-pyrimidyl 2-methyl-l-imidazolyl 839 CH2OCH3 2-pyrimidyl 5-methyl-l-imidazolyl 840 CHOCH3 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
841 CH2OCH3 5-pyrimidyl 2- (aminosulfonyl)phenyl 842 CH2OCH3 5-pyrimidyl 2- (methylaminosulfonyl) phenyl 843 CH2OCH3 5-pyrimidyl 1-pyrrolidinocarbonyl 844 CH2OCH3 5-pyrimidyl 2- (methylsulfonyl) phenyl 845 CHOCH3 5-pyrimidyl 4-morpho1ino 846 CH2OCH3 5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl) phenyl 847 CH2OCH3 5-pyrimidyl 4-morpholinocarbonyl 848 CH2OCH3 5-pyrimidyl 2-methyl-l-imidazolyl 849 CH2OCH3 5-pyrimidyl 5-methyl-l-imidazolyl 850 CH2OCH3 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
851 CH2OCH3 2-Cl-phenyl 2- (aminosulfonyl)phenyl 852 CH2OCH3 2-Cl-phenyl 2- (methylaminosulfonyl) phenyl 853 CH2OCH3 2-Cl-phenyl 1-pyrrolidinocarbonyl 854 CHOCH3 2-Cl-phenyl 2- (methylsulfonyl) henyl 855 CH2OCH3 2-Cl-phenyl 4-morpho1ino 856 CH2OCH3 2-Cl-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 857 CH2OCH3 2-Cl-phenyl 4-morpholinocarbonyl 858 CH2OCH3 2-Cl-phenyl 2-methyl-l-imidazolyl 859 CH2OCH3 2-Cl-phenyl 5-methyl-l-imidazolyl 860 CH2OCH3 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
861 CH2OCH3 2-F-phenyl 2- (aminosulfonyl)phenyl 862 CH2OCH3 2-F-phenyl 2- (methylaminosulfonyl) phenyl 863 CH2OCH3 2-F-phenyl 1-pyrrolidinocarbonyl 864 CH2OCH3 2-F-phenyl 2- (methylsulfonyl) phenyl 865 CH2OCH3 2-F-phenyl 4-morpholino 866 CH2OCH3 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl 867 CHOCH3 2-F-phenyl 4-morpho1inocarbony1 868 CH2OCH3 2-F-phenyl 2-methyl-l-imidazolyl 869 CH2OCH 2-F-phenyl 5-methyl-l-imidazolyl 870 CH2OCH3 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
871 CH2OCH3 2, 6-diF-phenyl 2- (aminosulfonyl) phenyl 872 CH2OCH3 2, 6-diF-phenyl 2- (methylaminosulfonyl) phenyl 873 CH2OCH3 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl 874 CH2OCH3 2, 6-diF-phenyl 2- (methylsulfonyl ) phenyl 875 CH2OCH3 2, 6-diF-phenyl 4-morpholino 876 CH2OCH3 2, 6-diF-phenyl 2- (1 ' -CF3-tetrazol-2-yl)phenyl 877 CH2OCH3 2, 6-diF-phenyl 4-morpholinocarbonyl 878 CH2OCH3 2, 6-diF-phenyl 2-methyl-l-imidazolyl 879 CH2OCH3 2, 6-diF-phenyl 5-methyl-l-imidazolyl 880 CH2OCH3 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
881 CONH2 phenyl 2- (aminosulfonyl) phenyl
882 CONH2 phenyl 2- (methylaminosulfonyl) phenyl
883 CONH2 phenyl 1-pyrrolidinocarbonyl
884 CONH2 phenyl 2- (methylsulfonyl) phenyl
885 CONH2 phenyl 4-morpholino
886 CONH2 phenyl 2- (1 ' -CF3-tetrazol-2-yl) phenyl
887 CONH2 phenyl 4-morpholinocarbonyl
888 CONH2 phenyl 2-methyl-l-imidazolyl
889 CONH2 phenyl 5-methyl-l-imidazolyl
890 CONH2 phenyl 2-methylsulfonyl-l-imidazolyl
891 CONH2 2-pyridyl 2- (aminosulfonyl)phenyl
892 C0NH2 2-pyridyl 2- (methylaminosulfonyl) phenyl
893 C0NH2 2-pyridyl 1-pyrrolidinocarbonyl
894 CONH2 2-pyridyl 2- (methylsulfonyl)phenyl
895 CONH2 2-pyridyl 4-morpho1ino
896 CONH2 2-pyridyl 2-(l'-CF3-tetrazol-2-yl)phenyl 897 CONH 2-pyridyl 4-morpholinocarbonyl
898 CONH2 2-pyridyl 2-methyl-l-imidazolyl
899 CONH2 2-pyridyl 5-methyl-l-imidazolyl
900 CONH2 2-pyridyl 2-methylsulfonyl-l-imidazolyl
901 CONH2 3-pyridyl 2- (aminosulfonyl)phenyl
902 CONH2 3-pyridyl 2- (methylaminosulfonyl)phenyl
903 CONH2 3-pyridyl 1-pyrrolidinocarbonyl
904 CONH2 3-pyridyl 2- (methylsulfonyl) phenyl
905 CONH2 3-pyridyl 4-morpholino
906 CONH2 3-pyridyl 2-(l' -CF3-tetrazol-2-yl) henyl
907 CONH2 3-pyridyl 4-morpho1inocarbony1
908 CONH2 3-pyridyl 2-methyl-l-imidazolyl
909 CONH2 3-pyridyl 5-methyl-l-imidazolyl
910 CONH2 3-pyridyl 2-methylsulfonyl-l-imidazolyl
911 CONH2 2-pyrimidyl 2- (aminosulfonyl)phenyl
912 CONH2 2-pyrimidyl 2- (methylaminosulfonyl) phenyl
913 CONH2 2-pyrimidyl 1-pyrro1idinocarbony1
914 CONH2 2-pyrimidyl 2- (methylsulfonyl) phenyl
915 CONH2 2-pyrimidyl 4-morpho1ino
916 CONH2 2-pyrimidyl 2- (l'-CF3-tetrazol-2-yDphenyl
917 CONH2 2-pyrimidyl 4-morpholinocarbonyl
918 CONH2 2-pyrimidyl 2-methyl-l-imidazolyl
919 CONH2 2-pyrimidyl 5-methyl-l-imidazolyl
920 CONH2 2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
921 CONH2 5-pyrimidyl 2- (aminosulfonyl) phenyl
922 CONH2 5-pyrimidyl 2- (methylaminosulfonyl)phenyl
923 CONH2 5-pyrimidyl 1-pyrrolidinocarbonyl
924 CONH2 5-pyrimidyl 2- (methylsulfonyl) phenyl
925 CONH2 5-pyrimidyl 4-morpholino
926 CONH2 5-pyrimidyl 2-(l'-CF3-tetrazol-2-yl)phenyl
927 CONH2 5-pyrimidyl 4-morpho1inocarbony1
928 CONH2 5-pyrimidyl 2-methyl-l-imidazolyl
929 CONH2 5-pyrimidyl 5-methyl-l-imidazolyl
930 CONH2 5-pyrimidyl 2-methylsulfonyl-l-imidazolyl
931 CONH2 2-Cl-phenyl 2- (aminosulfonyl) phenyl
932 CONH2 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl
933 CONH2 2-Cl-phenyl 1-py ro1idinocarbony1 934 CONH2 2-Cl-phenyl 2 - (methylsulfonyl ) phenyl
935 CONH2 2-Cl-phenyl 4 -morpho 1 ino
936 CONH2 2-Cl-phenyl 2- (1' -CF3-tetrazol-2-yDphenyl
937 CONH2 2-Cl-phenyl 4-morpholinocarbonyl
938 CONH2 2-Cl-phenyl 2-methyl-l-imidazolyl
939 CONH2 2-Cl-phenyl 5-methyl-l-imidazolyl
940 CONH2 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
941 CONH2 2-F-phenyl 2- (aminosulfonyl)phenyl 942 CONH2 2-F-phenyl 2- (methylaminosulfonyl)phenyl 943 C0NH2 2-F-phenyl 1-pyrrolidinocarbonyl 944 CONH2 2-F-phenyl 2- (methylsulfonyl) phenyl 945 CONH2 2-F-phenyl 4-morpho1ino 946 CONH2 2-F-phenyl 2-(l' -CF3-tetrazol-2-yDphenyl 947 CONH2 2-F-phenyl 4-morpho1inocarbony1 948 CONH2 2-F-phenyl 2-methyl-l-imidazolyl 949 CONH2 2-F-phenyl 5-methyl-l-imidazolyl 950 CONH 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
951 CONH2 2, , 6-diF-phenyl 2- (aminosulfonyl)phenyl
952 CONH2 2, , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
953 CONH2 2, , 6-diF-phenyl 1-pyrrolidinocarbonyl
954 CONH2 2, , 6-diF-phenyl 2- (methylsulfonyl) phenyl
955 CONH2 2, , 6-diF-phenyl 4-morpholino
956 CONH2 2, , 6-diF-phenyl 2- ( D -CF3 - tetrazol-2 -yD phenyl
957 CONH2 2, , 6-diF-phenyl 4-morpholinocarbonyl
958 CONH2 2, .6-diF-phenyl 2-methyl-l-imidazolyl
959 CONH2 2, 6-diF-phenyl 5-methyl-l-imidazolyl
960 CONH2 2, 6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
Table 2
Figure imgf000084_0001
Figure imgf000084_0002
i J
Figure imgf000085_0001
Figure imgf000085_0002
Figure imgf000086_0001
w
Figure imgf000086_0002
aa
Figure imgf000086_0003
ee gg
Figure imgf000086_0004
hh
Figure imgf000087_0001
qq rr ss
Ex # A B
1 phenyl 2- (aminosulfonyl) phenyl
2 phenyl 2- (methylaminosulfonyl)phenyl
3 phenyl 1-pyrrolidinocarbonyl
4 phenyl 2- (methylsulfonyl) phenyl
5 phenyl 4-morpho1ino
6 phenyl 2- ( l ' -CF3 -tetrazol-2 -yD phenyl
7 phenyl 4-morpho1inocarbony1
8 phenyl 2-methyl-l-imidazolyl
9 phenyl 5-methyl-l-imidazolyl
10 phenyl 2-methylsulfonyl-l-imidazolyl
11 2-pyridyl 2- (aminosulfonyl) phenyl
12 2-pyridyl 2- (methylaminosulfonyl)phenyl
13 2-pyridyl 1-pyrro1idinocarbony1
14 2-pyridyl 2- (methylsulfonyl) phenyl
15 2-pyridyl 4-morpho1ino
16 2-pyridyl 2- (1' -CF3-tetrazol-2-yl)phenyl
17 2-pyridyl 4-morpholinocarbony1 2-pyridyl 2-methyl-l-imidazolyl
2-pyridyl 5-methyl-l-imidazolyl
2-pyridyl 2-methylsulfonyl-l-imidazolyl
3-pyridyl 2- (aminosulfonyl) phenyl
3-pyridyl 2- (methylaminosulfonyl) phenyl
3-pyridyl 1-pyrro1idinocarbony1
3-pyridyl 2- (methylsulfonyl) phenyl
3-pyridyl 4-morpholino
3-pyridyl 2- (l'-CF3-tetrazol-2-yDphenyl
3-pyridyl 4-morpho1inocarbony1
3-pyridyl 2-methyl-l-imidazolyl
3-pyridyl 5-methyl-l-imidazolyl
3-pyridyl 2-methylsulfonyl-1-imidazolyl
2-pyrimidyl 2- (aminosulfonyl)phenyl
2-pyrimidyl 2- (methylaminosulfonyl) phenyl
2-pyrimidyl 1-pyrrolidinocarbonyl
2-pyrimidyl 2- (methylsulfonyl) phenyl
2-pyrimidyl 4-morpholino
2-pyrimidyl 2- (1' -CF3-tetrazol-2-yDphenyl
2-pyrimidyl 4-morpholinocarbonyl
2-pyrimidyl 2-methyl-l-imidazolyl
2-pyrimidyl 5-methyl-l-imidazolyl
2-pyrimidyl 2-methylsulfonyl-l-imidazolyl
5-pyrimidyl 2- (aminosulfonyl) phenyl
5-pyrimidyl 2- (methylaminosulfonyl) phenyl
5-pyrimidyl 1-pyrrolidinocarbonyl
5-pyrimidyl 2- (methylsulfonyl) phenyl
5-pyrimidyl 4-morpho1ino
5-pyrimidyl 2- (1' -CF3-tetrazol-2-yl)phenyl
5-pyrimidyl 4-morpholinocarbonyl
5-pyrimidyl 2-methyl-l-imidazolyl
5-pyrimidyl 5-methyl-l-imidazolyl
5-pyrimidyl 2-methylsulfonyl-l-imidazolyl 2-Cl-phenyl 2- (aminosulfonyl) phenyl 2-Cl-phenyl 2- (methylaminosulfonyl)phenyl 2-Cl-phenyl 1-pyrrolidinocarbonyl 2-Cl-phenyl 2- (methylsulfonyl) phenyl 55 2-Cl-phenyl 4-morpholino
56 2-Cl-phenyl 2- (l'-CF3-tetrazol-2-yDphenyl
57 2-Cl-phenyl 4-morpholinocarbonyl
58 2-Cl-phenyl 2-methyl-l-imidazolyl
59 2-Cl-phenyl 5-methyl-l-imidazolyl
60 2-Cl-phenyl 2-methylsulfonyl-l-imidazolyl
61 2-F-phenyl 2- (aminosulfonyl) phenyl
62 2-F-phenyl 2- (methylaminosulfonyl)phenyl
63 2-F-phenyl 1-pyrro1idinocarbony1
64 2-F-phenyl 2- (methylsulfonyl) phenyl
65 2-F-phenyl 4-morpholino
66 2-F-phenyl 2- (1 ' -CF3-tetrazol-2-yDphenyl
67 2-F-phenyl 4-morpholinocarbonyl
68 2-F-phenyl 2-methyl-l-imidazolyl
69 2-F-phenyl 5-methyl-l-imidazolyl
70 2-F-phenyl 2-methylsulfonyl-l-imidazolyl
71 2,6-diF-phenyl 2- (aminosulfonyl) phenyl
72 2 , 6-diF-phenyl 2- (methylaminosulfonyl) phenyl
73 2 , 6-diF-phenyl 1-pyrrolidinocarbonyl
74 2,6-diF-phenyl 2- (methylsulfonyl) phenyl
75 2,6-diF-phenyl 4-morpholino
76 2,6-diF-phenyl 2-(l' -CF3-tetrazol-2-yl) phenyl
77 2,6-diF-phenyl 4-morpholinocarbonyl
78 2,6-diF-phenyl 2-methyl-l-imidazolyl
79 2,6-diF-phenyl 5-methyl-l-imidazolyl
80 2,6-diF-phenyl 2-methylsulfonyl-l-imidazolyl
Utility The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa or thrombin. The effectiveness of compounds of the present invention as inhibitors of factor Xa was determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) was measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which was monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Ki .
Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCI, and 0.5 % PEG 8000. The Michaelis constant, Km, for substrate hydrolysis was determined at 25°C using the method of
Lineweaver and Burk. Values of Ki were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 ιriM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship was used to calculate Ki values:
(v0-vs)/vs = I/(Ki (1 + S/K )) where: v0 is the velocity of the control in the absence of inhibitor; vs is the velocity in the presence of inhibitor; I is the concentration of inhibitor;
Ki is the dissociation constant of the enzyme : inhibitor complex;
S is the concentration of substrate; K is the Michaelis constant. Using the methodology described above, a compound of the present invention were found to exhibit a Ki of <10 uM, thereby confirming the utility of the compounds of the present invention as effective Xa inhibitors. The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae. The AV shunt device consists of a piece of 6-cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV- shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt. The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression. The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes .
Some compounds of the present invention were shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vitro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem. 265, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin- mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) was monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCI, and 0.5% PEG 6000, was incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity was assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk. Using the methodology described above, some compounds of this invention were evaluated and found to exhibit a K of less than 10 μm, thereby confirming the utility of the compounds of the present invention as effective thrombin inhibitors .
The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anti- coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents , thrombin inhibitors , or thrombolytic or fibrinolytic agents .
The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of
Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease. By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.
The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) , and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof . Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include lib/Ilia antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof .
The term thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application Publication Number 293 881 A2, the disclosures of which are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471,651 A2, the disclosures of which are hereby incorporated herein by reference. The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) . Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase .
Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety. The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa. For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols , compounds according to the present invention could be used to test their effectiveness. The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present.
Dosaσe and Formulation
The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations) , pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice . The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches . When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices .
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, annitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids , such as cholesterol, stearylamine, or phosphatidylcholines .
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers . Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-pheno1, polyhydroxyethylaspartamidephenol, or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans , polycyanoacylates , and crosslinked or amphipathic block copolymers of hydrogels .
Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets . Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours . Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions . Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances . Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol .
Suitable pharmaceutical carriers are described in Remington ' s Pharmaceutical Sciences . Mack Publishing Company, a standard reference text in this field. Representative useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows : Capsules A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. Soft Gelatin Capsules
A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried. Tablets
Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. In ectable
A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized.
Suspension
An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin.
Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit .
Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight .
Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.
Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination. Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced) . For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines . One of the active ingredients may also be coated with a material which effects a sustained- release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a lowviscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components . The polymer coating serves to form an additional barrier to interaction with the other component.
These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings . It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims

WHAT IS CLAIMED IS ;
1. A compound of formula I :
Figure imgf000102_0001
I II or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
M1 is N or CRlc;
M2 is NRla or CRlaRla, provided that only one of M1 and M2 is a N atom;
D is selected from C (=NR8) NR7R9 , NHC (=NR8) NR7R9 , NR8CH(=NR7), C(0)NR7R8, and CR8R9NR7R8;
E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, and piperidinyl substituted with 1 R;
alternatively, D-E-G together represent pyridyl substituted with 1 R;
R is selected from H, Cl, F, Br, I, (CH )tOR3, C1-4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8;
G is selected from NHCH2, OCH2, and SCH , provided that when s is 0, then G is absent;
Z is selected from a Cι_4 alkylene, (CH2)rO(CH2) τ,
(CH2 )r R3(CH2 )r, (CH2 ) rC (O) (CH2) r, (CH2) rC (0) 0 (CH2) τ, (CH2)rOC(0) (CH2)r, (CH2)rC(0)NR3(CH2)r, (CH2)r R3C(0) (CH2)r, (CH2) rOC (0) 0 (CH2) r, (CH2)rOC(0)NR3(CH2)r, (CH2)rNRC(0)0(CH2)r, (CH2)rNRC(0)NR3 (CH2)r, (CH2) rS (O) p (CH2) r, (CH2)rS02NR3(CH2)r, (CH2 ) rNR3S02 (CH2 ) r, and (CH2)rNR3S02NR3 (CH2)r, provided that Z does not form a N- N, N-O, N-S, NCH2N, NCH0, or NCH2S bond with group A;
Rla and Rlb are, at each occurrence, independently selected from H, -(CH2)r-R1', NCH2R1", OCH2R1", SCH2R1", N(CH2 )2(CH2 )tR1', 0(CH2)2(CH2 )tR1'' and S (CH2 ) 2 (CH2 ) tR1' ;
Rlc is selected from H, -(CH2)g-R1', C1-.3 alkyl, C(0)R2c, (CF2)rC02R2c, C(0)NR2R2a, C3-6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
R1' is selected from H, C╬╣_3 alkyl, halo, (CF2)rCF3, OR2, NR2R2a, C(0)R2c, 0C(0)R2, (CF2) rC02R2c, S(0)pR2b, NR2(CH2)rOR2, NR2C(0)R2b, NR2C (0)NHR2b, NR2C(0)2R2a, OC(0)NR2b, C(0)NR2R2a, S02NR2R2a, NR2S02R2b, C3_6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4;
R1" is selected from H, C(0)R2b, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a;
R2, at each occurrence, is selected from H, CF3, Cχ-6 alkyl, benzyl, C3-.6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
Ra, at each occurrence, is selected from H, CF3 , Cχ-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2
Rb, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b; R2b, at each occurrence, is selected from CF3, C╬╣_4 alkoxy,
C╬╣_6 alkyl, benzyl, C3_6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3 , OH, C1-.4 alkoxy, C1-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 Rb;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 Rb which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, C1-4 alkyl, and phenyl;
R3a, at each occurrence, is selected from H, C╬╣_4 alkyl, and phenyl ;
A is selected from:
C3-.10 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
B is selected from:
X-Y, NR2R2 , C(=NR2)NR2R2a, NR2C (=NR2 ) NR2R2a, C3-.10 carbocyclic residue substituted with 0-2 Ra, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a; X is selected from C3.-4 alkylene, -CR2 (CR2R2b) (CH2) t~ Γûá -C(O)- -C(=NR)-, -CR2(NR1"R2)-, -CR2(OR2)-, -CR2(SR2)-, -C(0)CR2R2a-, -CR2RaC(0), -S(0)p-, -S (0)pCR2R2a-, -CR2R2aS(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (0) 2CR2R2a-, -CR2R2aS(0)2NR2-, -NR2S(0)2NR2-, -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C(0)CR2R2a-, -CR2R2aC (O)NR2-, -CR2R2aNR2C(0)-, -NR2C(0)0-, -OC(0)NR2-, -NR2C (O)NR2-, -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO-, and
-OCR2R2a- ;
Y is selected from:
(CH2)rNR2R2a, provided that X-Y do not form a N-N, 0-N, or S-N bond,
C3-.10 carbocyclic residue substituted with 0-2 R4a, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from =0, (CH2)rOR2/ halo, C╬╣_ alkyl, -CN, N02, (CH2) rNR2R2a, (CH2) rC (0) R2b,
NR2C(0)R2b, C(0)NR2R2a, NR2C (0)NR2R2a, CH (=NR2) NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-C╬╣_4 alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, NCH2R1", OCH2R1", SCH2R1", N(CH2)2(CH2)tR1', 0(CH2)2(CH2)tR1', and S(CH2)2(CH2)tR1',
alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S;
R , at each occurrence, is selected from =0, (CH2)rOR2' halo, C╬╣_4 alkyl, -CN, N02, (CH2) rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, C(0)NR2R2a, NR2C (0)NR2R2a, CH (=NR2) NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-C╬╣_ alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3; alternatively, one Ra is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R5;
R4 , at each occurrence, is selected from =0, (CH2)rOR3, halo, Ci-4 alkyl, -CN, N02, (CH2) rNR3R3a, (CH2) rC (0) R3 , NR3C(0)R3a, C(0)NR3R3a, NR3C (0)NR3R3a, CH(=NR3 )NR3R3 , NH3C(=NR3)NR3R3a, S02NR3R3 , NR3S02NR3R3a, NR3S╬╕2-C╬╣_4 alkyl, NR3S02CF3, NR3S02-phenyl , S(0)PCF3, S(0)p-Ci- alkyl, S (0)p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF3, C╬╣_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, OH, (CH2)rOR2, halo, C1-4 alkyl, CN, N02 , (CH2) rNR2Ra, (CH2) rC (0)R2b, NR2C(0)R2b, NR2C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S╬╕2NR2R2 , and NR2S02Ci-4 alkyl;
R7, at each occurrence, is selected from H, OH, C╬╣_6 alkyl, C╬╣_6 alkylcarbonyl , C┬▒-╬▓ alkoxy, C1-.4 alkoxycarbonyl, (CH2)n-phenyl, C╬┤-io aryloxy, C╬▓-io aryloxycarbonyl , C╬┤-io arylmethylcarbonyl , C1-4 alkylcarbonyloxy C1-4 alkoxycarbonyl, C╬▓-io arylcarbonyloxy C╬╣_4 alkoxycarbonyl, C1-6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl C1-4 alkoxycarbonyl;
R8, at each occurrence, is selected from H, C╬╣_6 alkyl and (CH2)n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R9, at each occurrence, is selected from H, Ci-e alkyl and (CH2)n-phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3;
m, at each occurrence, is selected from 0, 1, and 2;
p, at each occurrence, is selected from 0, 1, and 2;
q, at each occurrence is selected from 1 and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0 and 1.
2. A compound according to Claim 1 , wherein the compound is of formula la or lb:
Figure imgf000107_0001
wherein;
Z is selected from a CH20, OCH2, CH2NH, NHCH2, C(O), CH2C(0), C(0)CH2, NHC(O), C(0)NH, CH2S(0)2, S(0)2(CH2), S02NH, and NHSO2, provided that Z does not form a N-N, N-O, NCH2N, or NCH2O bond with group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2,3 -thiadiazolyl , 1,2, 4-thiadiazolyl ,
1, 2 , 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3 -triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, 1, 3 , 4-triazolyl, benzofuranyl , benzothiofuranyl , indolyl, benzimidazolyl, benzoxazolyl , benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl , and isoindazolyl ;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2a, and NR2C(=NR2)NR2R2a;
X is selected from C1-4 alkylene, -C(O)-, -C(=NR)-,
-CR2(NR2R2a)-, -C(0)CR2R2 -, -CR2R2aC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (0) CR2R2a-, -CR2R2aC(0)NR2-, -CR2R2aNR2C (O) - , -NR2C (0) NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO- , and -OCR2R2a-;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R a; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl , thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2, 3-oxadiazolyl, 1, 2 , 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2 , 3-thiadiazolyl, 1, 2, 4-thiadiazolyl,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, 1,
3 , 4-triazolyl, benzofuranyl , benzothiofuranyl , indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems :
Figure imgf000109_0001
K is selected from 0, S, NH, and N.
A compound according to Claim 2, wherein;
Z is selected from a C(0), CH2C(0), C(0)CH , NHC(O), C(0)NH, C(0)N(CH3), CH2S(0)2, S(0)2(CH2), S02NH, and NHS02, provided that Z does not form a N-N or NCH2N bond with group A.
4. A compound according to Claim 3, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from C(0)NH2, C(=NH)NH2, CHNH2, CH2NHCH3 , CH(CH3)NH2, and C(CH3)2NH2; and,
R is selected from H, OCH3 , Cl, and F.
5. A compound according to Claim 4, wherein;
D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3- (methylaminomethyl) phenyl, 3- ( 1- aminoethyl) phenyl , 3- (2-amino-2-propyl) phenyl , 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3-(methylaminomethyl) phenyl, 4-fluoro-3-amidinophenyl, 4- fluoro-3-aminomethylphenyl , 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl) pyrid-2-yl , 6- ( 1-aminoethyl) pyrid-2- yl, and 6- (2-amino-2-propyl)pyrid-2-yl.
6. A compound according to Claim 3, wherein;
Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
R4, at each occurrence, is selected from OH, (CH2)rOR2 halo, C╬╣-4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R4a is selected from C1-4 alkyl, CF3, S(0)pR5, S02NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C╬╣_6 alkyl, phenyl, and benzyl;
X is CH2 or C(O); and,
Y is selected from pyrrolidino and morpholino.
7. A compound according to Claim 6, wherein;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl, 2-aminophenyl, and 2- methoxyphenyl ; and, B is selected from the group: 2-CF3 -phenyl, 2-
(aminosulfonyl ) phenyl , 2- (methylaminosulfonyl ) phenyl , 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl , 4-morpholino, 2- (1 ' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3 -triazolyl .
8. A compound according to Claim 3, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
D is selected from C(0)NH2, C(=NH)NH2, CH2NH2, CH2NHCH3, CH(CH3)NH2, and C(CH3)2NH2; and,
R is selected from H, OCH3 , Cl, and F;
Z is C(0)CH and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4; and,
B is selected from X-Y, phenyl, pyrrolidino, morpholino,
1, 2, 3-triazolyl, and imidazolyl, and is substituted with 0-1 Ra;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo, C1-4 alkyl, (CH2)rNR2R2a, and (CF2)rCF3;
R4a is selected from C1-4 alkyl, CF3, S(0)pR5, S02NR2R2a, and I-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, Cχ_6 alkyl, phenyl, and benzyl; X is CH2 or C(O); and,
Y is selected from pyrrolidino and morpholino.
9. A compound according to Claim 8 wherein;
D-E is selected from 3-amidinophenyl, 3-aminomethylphenyl, 3- aminocarbonylphenyl , 3- (methylaminomethyl)phenyl, 3- (1- aminoethyl) phenyl, 3- (2-amino-2-propyl) phenyl , 4-chloro- 3-amidinophenyl, 4-chloro-3-aminomethylphenyl, 4-chloro- 3- (methylaminomethyl) phenyl , 4-fluoro-3-amidinophenyl , 4- fluoro-3-aminomethylphenyl, 4-fluoro-3- (methylaminomethyl) phenyl, 6-amidinopyrid-2-yl, 6- aminomethylpyrid-2-yl, 6-aminocarbonylpyrid-2-yl, 6- (methylaminomethyl)pyrid-2-yl, 6- (l-aminoethyl)pyrid-2- yl, 6- (2-amino-2-propyl)pyrid-2-yl;
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl, and 2- methoxyphenyl ; and,
B is selected from the group: 2-CF3-phenyl, 2-
(aminosulfonyl) phenyl , 2- (methylaminosulfonyl) phenyl , 2- (dimethylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl)phenyl, 4-morpholino, 2- (1' -CF3~tetrazol- 2-yl)phenyl, 4-morpholinocarbonyl, 2-methyl-l-imidazolyl, 5-methyl-l-imidazolyl, 2-methylsulfonyl-l-imidazolyl and, 5-methyl-l, 2, 3-triazolyl .
10. A compound according to Claim 9 , wherein the compound is of formula la.
11. A compound according to Claim 9 , wherein the compound is of formula lb.
12. A compound according to Claim 3, wherein;
D is selected from C (=NR8) NR7R9 , C(0)NR7R8, NR7R8 , and CH2NR7R8 ;
E is phenyl substituted with R or pyridyl substituted with R;
R is selected from H, Cl, F, OR3, CH3, CH2CH3 , OCF3, and CF3;
Z is selected from C(O), CHC(0), C(0)CH2, NHC(O), and C(0)NH, provided that Z does not form a N-N bond with group A;
Rla and Rlb are, at each occurrence, independently selected from H, -(CH^r-R1', NCH2R1", OCH2R1", SO^R1", N(CH2)2(CH2)tR1', 0(CH2)2(CH2)tR1', and S (CH2) 2 (CH2) tRl' ;
Rlc is selected from H, -(CH^g-R1', C1-3 alkyl, C(0)R2c, (CF2)rC02R2c, and C(0)NR2R2a;
R1', at each occurrence, is selected from H, C1-.3 alkyl, halo, (CF )rCF3, OR2, NR2R2 , C(0)R2c, (CF2) rC0R2c, S(0)pR2b, NR2(CH2)rOR2, NR2C(0)R2b, NR2C(0)2R2b, C(0)NR2R2a, S02NR2R2 , and NR2S0R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
B is selected from: Y, X-Y, NR2R2a, C (=NR2)NR2R2a, and NR2C (=NR2) NR2R2a; X is selected from CH2, -CR2 (CR2R2b) (CH2) t-, -C(O)-, -C(=NR)-, -CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2- , -NR2-, and 0;
Y is NR2R2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1, 2 , 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2, 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1,3, 4-triazolyl;
R4, at each occurrence, is selected from =0, OH, Cl, F, C1-4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2b, NR2C(0)R2b, C(0)NR2R2a, CH(=NH)NH2, NHC(=NH)NH , S02NR2R2a, NR2S02-C╬╣_ alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
R4a, at each occurrence, is selected from =0, OH, Cl, F, C1-.4 alkyl, (CH2) rNR2R2a, (CH2) rC (0)R2b, NR2C(0)R2b, C(0)NRR2a, CH(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02-Ci-4 alkyl, NR2S02R5, S(0)PR5, (CF2)rCF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C╬╣_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, =0, OH, OR2, Cl, F, CH3, CN, N02, (CH2)r R2R2a, (CH2) rC (0)R2b, NR2C(0)R2b, CH(=NH)NH2, NHC(=NH)NH2, and S02NR2R2a; R7, at each occurrence, is selected from H, OH, Cχ_6 alkyl, Cι_β alkylcarbonyl, Cχ_6 alkoxy, C1-.4 alkoxycarbonyl, benzyl, Cβ-io aryloxy, Cβ-io aryloxycarbony1 , Cβ-io arylmethylcarbony1, C1-.4 alkylcarbonyloxy C1-.4 alkoxycarbonyl, Cg-io arylcarbonyloxy C1-4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl , phenylaminocarbonyl , and phenyl Cι_4 alkoxycarbonyl ;
R8, at each occurrence, is selected from H, C1-6 alkyl and benzyl; and
alternatively, R7 and R8 combine to form a morpholino group; and,
R9, at each occurrence, is selected from H, C╬╣_e alkyl and benzyl .
13. A compound according to Claim 12, wherein;
E is phenyl substituted with R or 2-pyridyl substituted with R;
R is selected from H, Cl, F, OCH3, CH3, OCF3, and CF3;
Z is selected from a C(0)CH2 and C(0)NH, provided that Z does not form a N-N bond with group A;
Rla, at each occurrence, is selected from H, CH3, CHCH3, Cl, F, CF3, OCH3, NR2R2a, S(0)pR2b, CH2S(0)pR2b,
CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2a, and S02NR2R2a;
Rib is selected from H, CH3, CH2CH3, Cl, F, CF3, OCH3, NR2R2a, S(0)pR2b, CH2S(0)pR2b, CH2NR2S (0)pR2b, C(0)R2c, CH2C(0)R2c, C(0)NR2R2a, and S02NR2R2 ; RIC is selected from H, CH3, CHCH3, CF3, CH2S(0)pR2b,
CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2 , and C(0)NR2R2a;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, pyrimidyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, and imidazolyl;
B is selected from: Y and X-Y;
X is selected from CH2, -CR2 (CR2R2b) -, -C(O)-, -C(=NR)-,
-CH(NR2R2a)-, -C(0)NR2-, -NR2C(0)-, -NR2C (O)NR2- , -NR2-, and 0;
Y is NRR2a, provided that X-Y do not form a N-N or 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2 , 4-oxadiazolyl, 1, 2, 5-oxadiazolyl, 1, 3 , 4-oxadiazolyl, 1,2, 3-thiadiazolyl, 1,2, 4-thiadiazolyl,
1,2, 5-thiadiazolyl, 1, 3 , 4-thiadiazolyl, 1, 2 , 3-triazolyl, 1,2, 4-triazolyl, 1, 2, 5-triazolyl, and 1, 3 , 4-triazolyl;
R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
Rb, at each occurrence, is selected from CF3, OCH3, CH3, benzyl, and phenyl; R2c, at each occurrence, is selected from CF3, OH, OCH3, CH3, benzyl, and phenyl;
alternatively, R2 and R2a combine to form a 5 or 6 membered saturated, partially unsaturated, or unsaturated ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
R3, at each occurrence, is selected from H, CH3, CH2CH3, and phenyl ;
R3a, at each occurrence, is selected from H, CH3, CH2CH3, and phenyl ;
R4 , at each occurrence , is selected from OH, Cl , F , CH3 ,
CH2CH3 , NR2R2a , CH2NR2R2a, C (0 ) R2b , NR2C (0) R2b, C (0) NR2R2a , and CF3 ;
Ra, at each occurrence, is selected from OH, Cl, F, CH3,
CH2CH3, NR2R2a, CH2NR2R2a, C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, CF3, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3, C╬╣_6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 1 R6;
R6, at each occurrence, is selected from H, OH, OCH3, Cl, F, CH3, CN, N02, NR2R2a, CH2NR2R2a, and S02NR2R2a;
R7, at each occurrence, is selected from H, OH, Cι_3 alkyl, Cι_3 alkylcarbonyl, C1-.3 alkoxy, C1-.4 alkoxycarbonyl, benzyl, phenoxy, phenoxycarbonyl , benzylcarbonyl, C1-.4 alkylcarbonyloxy C1-.4 alkoxycarbonyl, phenylcarbonyloxy Cχ_4 alkoxycarbonyl, C1-6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl Cχ_4 alkoxycarbonyl; R8, at each occurrence, is selected from H, CH3, and benzyl; and,
alternatively, R7 and R8 combine to form a morpholino group;
R9, at each occurrence, is selected from H, CH3, and benzyl.
14. A compound according to Claim 13, wherein;
Rla, at each occurrence, is selected from H, CH3, CHCH3, Cl, F, CF3, OCH3/ NR2R2a, S(0)pR2b, C(0)NR2R2 , CH2S(0)pR2b, CH2NR2S(0)pR2b, C(0)R2c, CH2C(0)R2c, and S02NR2R2a;
Rlb is selected from H, CH3, CH2CH3, Cl, F, CF3, OCH3, NR2R2a, S(0)pR2b, C(0)NR2R2a, CH2S(0)pR2b, CH2NR2S (0) pR2b, C(0)R2b, CHC(0)R2b, and S02NR2R2a;
Rlc is selected from H, CH3, CH2CH3, CF3, C(0)NR2R2a, CHS(0)pR2b, CH2NR2S(0)pR2b, C(0)R2b, and CH2C(0)R2b;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4; phenyl, pyridyl, and pyrimidyl;
B is selected from: Y and X-Y;
X is selected from -C(O)- and O;
Y is NR2R2a, provided that X-Y do not form a 0-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ; R2, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3, CH3, benzyl, and phenyl;
R2b, at each occurrence, is selected from CF3, OCH3, CH3, benzyl, and phenyl;
R2c, at each occurrence, is selected from CF3, OH, OCH3 , CH3, benzyl, and phenyl;
alternatively, R2 and R2 combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;
R4, at each occurrence, is selected from Cl, F, CH3, NR2R2a, and CF3;
Ra, at each occurrence, is selected from Cl, F, CH3 , S02NR2R2a, S(0)PR5, and CF3 ; and,
R5, at each occurrence, is selected from CF3 and CH3.
15. A compound according to Claim 1, wherein the compound is selected from the group:
1- (3-amidinophenyl) -5- [ [ (2 ' -methylsulfonyl- [1, 1 ' ] -biphen-4- yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline; and,
1- (3-aminomethylphenyl) -5- [ [ (2 ' -methylsulfonyl- [1,1'] -biphen- 4-yl) -aminocarbonyl] -3-trifluoromethyl-pyrazoline;
and pharmaceutically acceptable salts thereof.
16. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claims 1-15 or a pharmaceutically acceptable salt thereof.
17. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-15 or a pharmaceutically acceptable salt thereof.
PCT/US1999/006310 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors WO1999050255A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU31109/99A AU3110999A (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors
EP99912828A EP1064270B1 (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors
AT99912828T ATE278673T1 (en) 1998-03-27 1999-03-23 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS
CA002321538A CA2321538A1 (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors
JP2000541159A JP2002509924A (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor Xa inhibitors
DE69920888T DE69920888T2 (en) 1998-03-27 1999-03-23 DISUBSTITUTED PYRAZOLINES AND TRIAZOLINES AS FACTOR XA INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7972598P 1998-03-27 1998-03-27
US60/079,725 1998-03-27

Publications (2)

Publication Number Publication Date
WO1999050255A2 true WO1999050255A2 (en) 1999-10-07
WO1999050255A3 WO1999050255A3 (en) 1999-11-18

Family

ID=22152402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006310 WO1999050255A2 (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors

Country Status (9)

Country Link
US (3) US6191159B1 (en)
EP (1) EP1064270B1 (en)
JP (1) JP2002509924A (en)
AT (1) ATE278673T1 (en)
AU (1) AU3110999A (en)
CA (1) CA2321538A1 (en)
DE (1) DE69920888T2 (en)
ES (1) ES2230841T3 (en)
WO (1) WO1999050255A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039131A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
WO2000066096A2 (en) * 1999-04-30 2000-11-09 Merab Lomia Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
WO2001029006A1 (en) * 1999-10-21 2001-04-26 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles and intermediates therefore
WO2002000655A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
US6949550B2 (en) 2001-12-04 2005-09-27 Bristol-Myers Squibb Company Substituted amino methyl factor Xa inhibitors
US6967208B2 (en) 2001-09-21 2005-11-22 Bristol-Myers Squibb Pharma Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7115627B2 (en) 2001-12-04 2006-10-03 Bristol-Myers Squibb Company Glycinamides as factor Xa inhibitors
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
US7338963B2 (en) 2001-09-21 2008-03-04 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
EP2194046A1 (en) * 2006-03-24 2010-06-09 Eisai R&D Management Co., Ltd. Triazolone derivative
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
US8012962B2 (en) 2004-03-12 2011-09-06 H. Lundbeck A/S Substituted thiomorpholine derivatives
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321538A1 (en) 1998-03-27 1999-10-07 Dupont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
PT1413331E (en) * 2001-01-26 2007-12-18 Schering Corp Combinations of the peroxisome proliferator-activated receptor (ppar) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications
ATE345793T1 (en) * 2001-09-21 2006-12-15 Schering Corp TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
AU2003236500B9 (en) * 2002-06-12 2009-07-02 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7208486B2 (en) * 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) * 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN101405275B (en) * 2006-03-24 2011-11-09 卫材R&D管理有限公司 Triazolone derivative
RU2557908C1 (en) * 2014-07-04 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Method of incubation of chicken eggs

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014683A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014682A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US5463071A (en) * 1991-07-27 1995-10-31 Dr. Karl Thomae Gmbh 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds
WO1997023212A1 (en) * 1995-12-21 1997-07-03 The Du Pont Merck Pharmaceutical Company ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS
WO1997030971A1 (en) * 1996-02-22 1997-08-28 The Du Pont Merck Pharmaceutical Company M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1998057951A1 (en) * 1997-06-19 1998-12-23 Du Pont Pharmaceuticals Company NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
WO1998057934A1 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5563158A (en) 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
WO1997047299A1 (en) * 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
CA2321538A1 (en) * 1998-03-27 1999-10-07 Dupont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463071A (en) * 1991-07-27 1995-10-31 Dr. Karl Thomae Gmbh 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
WO1995014683A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995014682A1 (en) * 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Isoxazoline compounds useful as fibrinogen receptor antagonists
WO1997023212A1 (en) * 1995-12-21 1997-07-03 The Du Pont Merck Pharmaceutical Company ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS
WO1997030971A1 (en) * 1996-02-22 1997-08-28 The Du Pont Merck Pharmaceutical Company M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1998057951A1 (en) * 1997-06-19 1998-12-23 Du Pont Pharmaceuticals Company NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
WO1998057934A1 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1064270A2 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100340559C (en) * 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 Nitrogen containing heterobicycles as factor XA inhibitors
US6413980B1 (en) 1998-12-23 2002-07-02 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
WO2000039131A1 (en) * 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
WO2000066096A2 (en) * 1999-04-30 2000-11-09 Merab Lomia Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
WO2000066096A3 (en) * 1999-04-30 2001-03-22 Merab Lomia Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
WO2001029006A1 (en) * 1999-10-21 2001-04-26 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles and intermediates therefore
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
US6465656B2 (en) * 1999-10-21 2002-10-15 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
WO2002000655A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors
US6506771B2 (en) 2000-06-23 2003-01-14 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl heterobicyclic factor Xa inhibitors
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6967208B2 (en) 2001-09-21 2005-11-22 Bristol-Myers Squibb Pharma Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US6989391B2 (en) 2001-09-21 2006-01-24 Bristol-Myers-Squibb Pharma Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US6995172B2 (en) 2001-09-21 2006-02-07 Bristol-Myers Squibb Pharma Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7005435B2 (en) 2001-09-21 2006-02-28 Bristol-Myers Squibb Pharma Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US9975891B2 (en) 2001-09-21 2018-05-22 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US8470854B2 (en) 2001-09-21 2013-06-25 Bristol-Meyers Squibb Company Lactam-containing compounds and derivatives thereof as factor XA inhibitors
US7960411B2 (en) 2001-09-21 2011-06-14 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US8188120B2 (en) 2001-09-21 2012-05-29 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7338963B2 (en) 2001-09-21 2008-03-04 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7371761B2 (en) 2001-09-21 2008-05-13 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7531535B2 (en) 2001-09-21 2009-05-12 Bristol-Meyers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
EP2105436A1 (en) 2001-09-21 2009-09-30 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor XA inhibitors
US7691846B2 (en) 2001-09-21 2010-04-06 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US6949550B2 (en) 2001-12-04 2005-09-27 Bristol-Myers Squibb Company Substituted amino methyl factor Xa inhibitors
US7115627B2 (en) 2001-12-04 2006-10-03 Bristol-Myers Squibb Company Glycinamides as factor Xa inhibitors
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US8012962B2 (en) 2004-03-12 2011-09-06 H. Lundbeck A/S Substituted thiomorpholine derivatives
US8299075B2 (en) 2004-03-12 2012-10-30 H. Lundbeck A/S Substituted thiomorpholine derivatives
US7816522B2 (en) 2006-03-24 2010-10-19 Eisai Co., Ltd. Triazolone derivatives
US7928228B2 (en) 2006-03-24 2011-04-19 Eisai Co., Ltd. Triazolone derivatives
EP2194046A1 (en) * 2006-03-24 2010-06-09 Eisai R&D Management Co., Ltd. Triazolone derivative
US8163787B2 (en) 2006-03-24 2012-04-24 Eisai R&D Management Co., Ltd. Triazolone derivatives
US7807690B2 (en) 2007-09-21 2010-10-05 Eisai R&D Management Co., Ltd. 2,3-dihydro-iminoisoindole derivatives
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Also Published As

Publication number Publication date
US6630468B2 (en) 2003-10-07
CA2321538A1 (en) 1999-10-07
WO1999050255A3 (en) 1999-11-18
JP2002509924A (en) 2002-04-02
EP1064270A2 (en) 2001-01-03
ES2230841T3 (en) 2005-05-01
US6436985B2 (en) 2002-08-20
US20010000179A1 (en) 2001-04-05
AU3110999A (en) 1999-10-18
DE69920888D1 (en) 2004-11-11
US6191159B1 (en) 2001-02-20
ATE278673T1 (en) 2004-10-15
EP1064270B1 (en) 2004-10-06
US20030105105A1 (en) 2003-06-05
DE69920888T2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
EP1064270B1 (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
US6426346B1 (en) 6-membered aromatics as factor Xa inhibitors
US6271237B1 (en) Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
US6599926B2 (en) Heteroaryl-phenyl substituted factor Xa inhibitors
EP0991638B1 (en) NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS
US6602871B2 (en) Thrombin or factor Xa inhibitors
EP1015429B1 (en) Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
EP0991625B1 (en) Inhibitors of factor xa with a neutral p1 specificity group
US6043257A (en) Amidinoindoles, amidinoazoles, and analogs thereof
EP0934265B1 (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
CA2293824A1 (en) (amidino)6-membered aromatics as factor xa inhibitors
WO1998001428A1 (en) AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
AU1724499A (en) Nitrogen containing heteroaromatics with ortho-substituted p1&#39;s as factor xa inhibitors
US6790845B2 (en) Fused heterocyclic inhibitors of factor Xa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR MX NO NZ PL SG SK UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN CZ EE HU IL IN JP KR MX NO NZ PL SG SK UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2321538

Country of ref document: CA

Ref country code: CA

Ref document number: 2321538

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999912828

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 541159

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999912828

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999912828

Country of ref document: EP